0001615774-17-004270.txt : 20170811 0001615774-17-004270.hdr.sgml : 20170811 20170811160608 ACCESSION NUMBER: 0001615774-17-004270 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170811 DATE AS OF CHANGE: 20170811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XG SCIENCES INC CENTRAL INDEX KEY: 0001435375 STANDARD INDUSTRIAL CLASSIFICATION: PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821] IRS NUMBER: 000000000 STATE OF INCORPORATION: MI FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-209131 FILM NUMBER: 171025049 BUSINESS ADDRESS: STREET 1: 3101 GRAND OAK DRIVE STREET 2: SUITE 212 CITY: LANSING STATE: MI ZIP: 48911 BUSINESS PHONE: 517-203-1110 MAIL ADDRESS: STREET 1: 3101 GRAND OAK DRIVE STREET 2: SUITE 212 CITY: LANSING STATE: MI ZIP: 48911 10-Q 1 s107106_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2017

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______to______.

	XG SCIENCES, INC.
	(Exact name of registrant as specified in its charter)

Michigan		333-209131		20-4998896
(State or other jurisdiction of incorporation or organization)		(Commission File No.)		(I.R.S. Employer Identification No.)

3101 Grand Oak Drive

Lansing, MI 48911

(Address of principal executive offices) (zip code)

(517) 703-1110

(Issuer Telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

(Note: Registrant is a voluntary filer of reports required to be filed by certain companies under Sections 13 and 15(d) of the Securities Exchange Act of 1934 and has filed all reports that would have been required during the preceding 12 months, had it been subject to such filing requirements.)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☑
(Do not check if a smaller reporting company)		Emerging growth company	☑

If an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☑

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No ☒

As of August 11, 2017, there were 2,100,225 shares outstanding of the registrant’s common stock.

XG SCIENCES, INC.

FORM 10-Q

June 30, 2017

INDEX

PART I

ITEM 1.	FINANCIAL STATEMENTS	4

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	16

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	27

ITEM 4.	CONTROLS AND PROCEDURES	27

PART II

ITEM 1.	LEGAL PROCEEDINGS	28

ITEM 1A.	RISK FACTORS	28

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	28

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	28

ITEM 4.	MINE SAFETY DISCLOSURES	28

ITEM 5.	OTHER INFORMATION	28

ITEM 6.	EXHIBITS	29

SIGNATURES		30

FORWARD-LOOKING STATEMENTS

The information in this Quarterly Report on Form 10-Q contains “forward-looking statements” and information within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) relating to XG Sciences, Inc., a Michigan corporation and its subsidiary, XG Sciences IP, LLC, a Michigan corporation (collectively referred to as “we”, “us”, “our”, “XG Sciences”, “XGS”, or the “Company”), which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenue, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth on beginning on page 14 under the section entitled “Risk Factors” in Post-Effective Amendment No. 5 (declared effective April 14, 2017) ) to our registration statement on Form S-1 (File No. 333-209131) as filed with the Securities and Exchange Commission (the “SEC”) on April 12, 2016, and originally declared effective on April 13, 2016 (the “Existing Registration Statement”).

XG SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2017			December 31, 2016
		(unaudited)
ASSETS

CURRENT ASSETS
Cash	$	431,107		$	1,785,343
Accounts receivable, less allowance for doubtful accounts of $10,000 at June 30, 2017 and December 31, 2016		131,607			99,078
Inventory		193,109			205,973
Incentive refunds receivable		—			165,635
Other current assets		213,789			174,495
Total current assets		969,612			2,430,524

PROPERTY, PLANT AND EQUIPMENT, NET		2,799,346			2,886,421

RESTRICTED CASH FOR LETTER OF CREDIT		195,644			195,499

INTANGIBLE ASSETS, NET		551,462			478,019

TOTAL ASSETS	$	4,516,064		$	5,990,463

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Accounts payable and other liabilities	$	750,359		$	964,757
Deferred revenue		7,120			6,428
Current portion of capital lease obligations		200,768			268,667
Total current liabilities		958,247			1,239,852

LONG TERM LIABILITIES
Long term portion of capital lease obligations		59,867			115,106
Long term debt		1,918,461			1,862,120
Derivative liability – warrants		7,798,653			7,900,249
Total long term liabilities		9,776,981			9,877,475

TOTAL LIABILITIES		10,735,228			11,117,327

STOCKHOLDERS’ DEFICIT
Series A convertible preferred stock, 3,000,000 shares authorized, 1,843,536 and 1,829,256 shares issued and outstanding, liquidation value of $22,122,432 and $21,951,072 at June 30, 2017 and December 31, 2016, respectively		21,805,940			21,634,597
Series B Preferred Stock, 1,500,000 shares authorized, 0 shares issued and outstanding, liquidation value of $0 at June 30, 2017 and December 31, 2016		—			—
Common stock, no par value, 25,000,000 shares authorized, 2,100,225 and 1,885,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively		17,134,739			15,647,839
Additional paid in capital		6,666,972			6,490,230
Accumulated deficit		(51,826,815	)		(48,899,530	)
Total stockholders’ deficit		(6,219,164	)		(5,126,864	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	4,516,064		$	5,990,463

See notes to unaudited condensed consolidated financial statements

XG SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016 (unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2017			2016			2017			2016

REVENUE
Product sales	$	259,079		$	82,035		$	416,779		$	141,777
Grants		—			137,055			99,489			158,365
Licensing revenue		25,000			25,000			50,000			50,000
Total revenue		284,079			244,090			566,268			350,142

COST OF GOODS SOLD
Direct costs		93,542			25,020			210,312			57,052
Unallocated manufacturing expenses		415,152			404,232			786,302			747,947
Total cost of goods sold		508,694			429,252			996,614			804,999

GROSS LOSS		(224,615	)		(185,162	)		(430,346	)		(454,857	)

OPERATING EXPENSES
Research and development		227,062			419,007			490,626			635,357
Sales, general and administrative		923,765			625,381			1,920,352			1,721,603
Total operating expenses		1,150,827			1,044,388			2,410,978			2,356,960

OPERATING LOSS		(1,375,442	)		(1,229,550	)		(2,841,324	)		(2,811,817	)

OTHER INCOME (EXPENSE)
Interest expense, net		(54,445	)		(101,123	)		(113,533	)		(184,774	)
Gain (Loss) from change in fair value of derivative liability – warrants		(53,056	)		142,848			101,596			232,614
Government incentives, net		(74,000	)		24,000			(74,024	)		48,000
Total other income (expense)		(181,501	)		65,725			(85,961	)		95,840

NET LOSS	$	(1,556,943	)	$	(1,163,825	)	$	(2,927,285	)	$	(2,715,977	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING –
Basic and diluted		2,054,193			887,595			1,986,834			862,069

NET LOSS PER SHARE – Basic and diluted	$	(0.76	)	$	(1.31	)	$	(1.47	)	$	(3.15	)

See notes to unaudited condensed consolidated financial statements

XG SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ (DEFICIT) FOR

THE SIX MONTHS ENDED JUNE 30, 2017

(unaudited)

	Preferred stock (A)				Preferred stock (B)				Common stock					Additional paid-in		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount			capital		deficit			Total
Balances, December 31, 2016		1,829,256	$	21,634,597		—	$	—		1,885,175	$	15,647,839		$	6,490,230	$	(48,899,530	)	$	(5,126,864	)
Stock issued for cash		—		—		—		—		215,050		1,720,400			—		—			1,720,400
Stock issuance fees and expenses		—		—		—		—		—		(233,500	)		—		—			(233,500	)
Preferred stock issued to pay capital lease obligations		14,280		171,343		—		—		—		—			—		—			171,343
Stock-based compensation		—		—		—		—		—		—			176,742		—			176,742
Net loss		—		—		—		—		—		—			—		(2,927,285	)		(2,927,285	)

Balances, June 30, 2017		1,843,536	$	21,805,940		—	$	—		2,100,225	$	17,134,739		$	6,666,972	$	(51,826,815	)	$	(6,219,164	)

See notes to unaudited condensed consolidated financial statements

XG SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND 2016 (unaudited)

	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(2,927,285	)	$	(2,715,977	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		439,078			456,133
Amortization of intangible assets		21,180			17,904
Stock-based compensation expense		176,742			228,126
Non-cash interest expense		114,295			157,903
Gain from change in fair value of derivative liability - warrants		(101,596	)		(232,614	)
(Increase) Decrease in:
Accounts receivable		(32,529	)		5,930
Inventory		12,864			12,624
Other current and non-current assets		126,196			(79,461	)
Increase (Decrease) in:
Accounts payable and other liabilities		(213,705	)		371,606
NET CASH USED IN OPERATING ACTIVITIES		(2,384,760	)		(1,777,826	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment		(352,003	)		(39,314	)
Purchases of intangible assets		(94,623	)		(53,647	)
NET CASH USED IN INVESTING ACTIVITIES		(446,626	)		(92,961	)

CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of capital lease obligations		(9,750	)		(2,832	)
Repayments of short-term notes		—			(750,000	)
Advances on short-term notes		—			574,750
Proceeds from issuance of common stock		1,720,400			2,285,032
Common stock issuance fees and expenses		(233,500	)		(336,600	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		1,477,150			1,770,350

NET DECREASE IN CASH		(1,354,236	)		(100,437	)
CASH AT BEGINNING OF PERIOD		1,785,343			1,060,224

CASH AT END OF PERIOD	$	431,107		$	959,787

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$	—		$	77,646

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING:
Value of preferred stock issued for AAOF capital lease obligations	$	171,343		$	171,343

See notes to unaudited condensed consolidated financial statements

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

NOTE 1 - NATURE OF BUSINESS AND BASIS OF PRESENTATION

XG Sciences, Inc., a Michigan company located in Lansing, Michigan and its subsidiary, XG Sciences IP, LLC (collectively referred to as “we”, “us”, “our”, or the “Company”) manufactures graphene nanoplatelets made from graphite, using two proprietary manufacturing processes to split natural flakes of crystalline graphite into very small and thin particles, which we sell as xGnP^® graphene nanoplatelets. We sell our nanoparticles in the form of bulk powders or dispersions to other companies for use as additives to make composite and other materials with specially engineered characteristics. We also manufacture and sell integrated, value-added products containing these graphene nanoplatelets such as greases, composites, thin sheets, inks and coating formulations that we sell to other companies. Additionally, we license our technology to other companies in exchange for royalties and other fees.

Basis of Presentation

The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and do not include all of the information and footnotes required by GAAP for complete financial statements. All intercompany transactions have been eliminated in consolidation.

Certain information and footnote disclosures normally included in our annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these interim condensed consolidated financial statements. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016, as filed with the Securities and Exchange Commission (“SEC”) on Form 10-K on March 31, 2017.

The results of operations presented in this quarterly report are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Liquidity

We have historically incurred losses from operations and we may continue to generate negative cash flows as we implement our business plan. Our condensed consolidated financial statements are prepared using US GAAP as applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

In December 2016, we entered into a draw loan note and agreement (the “Dow Facility”) with The Dow Chemical Company (“Dow”) to provide up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.

As of July 31, 2017, we had cash on hand of $1,000,702, and currently available funds of $2 million under the Dow Facility, which we believe will fund our operations for at least the next 12 months. We also have a commitment from a shareholder group, dated March 27, 2017, to provide up to $1 million of additional equity capital in the event we are unable to raise such funds from third party investors through the sale of our common stock in our initial public offering conducted pursuant to a Registration Statement on S-1 (Registration No. 333-209131) (the “IPO”). Our financial projections show that we may need to raise an additional $15 million or more before we are capable of achieving sustainable free cash flow after capital expenditures. We intend that the primary means for raising such funds will be through our IPO, the additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016. Thus far, we have raised $2.6 million through the sale of 323,578 shares of common stock between November 1, 2016 and June 30, 2017 towards the requirement to raise $10 million of additional equity capital in order to open up the remaining $5 million of availability on the Dow Facility. There can be no assurance that we will be able to raise additional equity capital in the IPO or in subsequent equity offerings or that the terms and conditions of any future financings will be workable or acceptable to us and our stockholders.

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

In the event we are unable to fund our operations from existing cash on hand, operating cash flows, additional borrowings or raising equity capital, we may be forced to reduce our expenses, slow down our growth rate, or discontinue operations. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Use of Estimates

The preparation of our condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, together with amounts disclosed in the related notes to the financial statements. Actual results and outcomes may differ from our estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these condensed consolidated financial statements include, but are not limited to, those related to revenue, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets, income taxes, the fair value of stock-based compensation and derivative financial instrument liabilities. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate.

Inventory

Inventory consists of raw materials, work-in-process and finished goods, all of which are valued at standard cost, which approximates average cost.

The following amounts were included in inventory at the end of the period:
	June 30,		December 31,
	2017		2016
Raw materials	$	37,411	$	45,964
Finished goods		155,698		160,009
Total	$	193,109	$	205,973

Derivative Financial Instruments

We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. The terms of convertible preferred stock and convertible notes that we issue are reviewed to determine whether or not they contain embedded derivative instruments that are required by ASC 815: “Derivatives and Hedging” to be accounted for separately from the host contract, and recorded at fair value. In addition, freestanding warrants are also reviewed to determine if they achieve equity classification. Certain stock warrants that we have issued did not meet the conditions for equity classification and are classified as derivative instrument liabilities measured at fair value. The fair values of these derivative liabilities are revalued at each reporting date, with the change in fair value recognized in earnings. See Note 5 for additional information.

Fair Value Measurements

The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:

	2017			2016

Balance at January 1	$	7,900,249		$	8,235,163
Warrants reclassified to equity		—			(51,417	)
Gain recognized in earnings		(101,596	)		(232,614	)
Balance at June 30	$	7,798,653		$	7,951,132

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

NOTE 3 — FINANCING AGREEMENTS

Dow Facility

In December 2016, we entered into the Dow Facility which provides us with up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available if we have raised $10 million of equity capital after October 31, 2016.

The Dow Facility is senior to most of our other debt, and is secured by all of our assets (Dow is subordinate only to the capital leases with AAOF, see note 9). The loan does not mature until December 1, 2021 (subject to certain mandatory prepayments based on our equity financing activities). Interest is payable beginning January 1, 2017 although we may elect to capitalize interest through January 1, 2019. Dow received warrant coverage of one share of common stock for each $40 in loans received by us, equating to 20% warrant coverage, with an exercise price of $8.00 per share for the warrants issued at closing with the initial $2 million draw. After the initial closing, future warrants are subject to adjustment if we sell shares of common stock at a lower price. As of June 30, 2017, we had issued 50,000 warrants to Dow, which are exercisable on or before the expiration date of December 1, 2023.

The warrants meet the criteria for classification within stockholders’ equity. During the six months ended June 30, 2017, amortization expense of $56,340 was recognized resulting in a carrying value of $1,918,461 for the Dow Facility as of June 30, 2017.

The Dow Facility entitles Dow to appoint an observer to our board of directors (the “Board”). Dow will maintain their observation right until the later of December 1, 2019; or when the amount of principal and interest outstanding under the Dow Facility is less than $5 million.

NOTE 4 — PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS

Private Placement

In April 2015, we commenced a private placement offering of Series B Units consisting of shares of Series B Preferred Stock and warrants to purchase common stock at an offering price of $16.00 per Series B Unit. During the period April 2015 through December 2016, we sold 266,887 shares of Series B Convertible Preferred Stock and Warrants to purchase 222,262 shares of common stock, for aggregate gross proceeds of $4,270,192.

The private placement Series B Unit offering was terminated on February 25, 2016. As a result of our IPO and pursuant to certain exchange rights granted to participants in the Series B Unit offering, holders of Series B Preferred Stock received the right to exchange each share of Series B Preferred Stock they owned into two shares of common stock. As of December 31, 2016, all holders of Series B Preferred Stock had exercised their Series B exchange rights, and as a result we issued 539,974 shares of restricted common stock in exchange for the 269,987 shares of Series B Preferred Stock that had been previously outstanding. All of the previously issued Series B Preferred Stock was cancelled. However, as of June 30, 2017, all of the 224,897 warrants issued in connection with the Series B Units remain outstanding. Such warrants have an exercise price of $16.00 per share and expire between April 21 and June 30, 2022.

NOTE 5 – DERIVATIVE LIABILITY WARRANTS

The Series A Convertible Preferred Stock warrants issued in conjunction with convertible notes issued in 2013 (subsequently converted into Series A Preferred Stock), equipment financing leases procured in 2013 and 2014, and certain other pre-emptive rights and the common stock warrants issued in connection with the 2015 Series B Unit offering are derivative liabilities which require re-measurement at fair value each reporting period. Liability classification is required because the terms of the underlying Series A Convertible Preferred Stock have a conversion price reset in the event we offer shares below the then current price of our common stock, and the exchange rights issued in connection with the Series B Unit offering are not consistent with the definition for financial instruments indexed only to a company’s own stock.

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

The initial value of the stock warrants issued as consideration for the equipment financing leases in 2013 and 2014 was recorded as a reduction of the capital lease obligation and is being amortized as part of the effective interest cost on the capital lease obligation (see Note 8).

In 2014 when we entered into financing agreements with Samsung, AAOF and XGS II, we provided our shareholders with preemptive rights to purchase shares of Series A Convertible Preferred Stock for every two shares of Series A Convertible Preferred Stock or Common Stock owned by the shareholder. In addition, for every two shares of Series A Convertible Preferred Stock purchased by a shareholder, we issued such shareholder a warrant to purchase one additional share of Series A Convertible Preferred Stock with the same terms as the warrants issued to AAOF and XGS II.

Also, as part of our private placement in April 2015, shareholders and holders of our convertible notes were provided the right to purchase their pro rata share of any class of stock that the Company sells or issues. The sale of Series B Preferred Stock in the April 2015 offering triggered the preemptive rights resulting in the issuance of shares of Series B Preferred Stock and warrants. As of June 30, 2017, the total number of Stock Warrants issued due to the preemptive rights offerings was 58,689.

Warrant shares indexed to derivative liabilities as of June 30, 2017 were as follows:

	Type of shares indexed	Exercise Price		Indexed Shares

Warrants issued with Secured Convertible Notes	Series A PS	$	6.40		833,333
Warrants issued with equipment financing leases	Series A PS	$	6.40		83,333
Warrants issued with Series A preemptive rights	Series A PS	$	6.40		56,054
Warrants issued with Series B preemptive rights	Common	$	16.00		2,635
Warrants issued with Series B Units	Common	$	16.00		222,262
Total shares indexed to derivative liabilities					1,197,617

The following table summarizes the fair value of the derivative liabilities as of June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31,2016

Warrants issued with Secured Convertible Notes	$	6,464,160	$	6,554,160
Warrants issued with equipment financing leases		646,418		655,418
Warrants issued with preemptive rights		437,775		443,790
Warrants issued with 2015 Series B Unit private placement		250,300		246,881
Total derivative liabilities	$	7,798,653	$	7,900,249

We estimated the fair value of their warrant derivative liabilities as of June 30, 2017 and December 31, 2016, using a lattice model and the following assumptions:

	June 30, 2017		December 31, 2016
Fair value of underlying stock		$8.00 - $12.64		$7.63 - $12.64
Equivalent risk free interest rate		1.43% - 1.56%		1.27%- 1.46%
Expected term (in years)		4.84 – 6.55		5.33- 7.04
Equivalent stock price volatility		37.49% - 37.69%		37.44%- 37.92%
Expected dividend yield		—		—

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

The value of the warrants is estimated using a binomial lattice model. Equivalent amounts reflect the net results of multiple modeling simulations that the lattice model applies to underlying assumptions. Because we are not publicly traded on a national exchange or to our knowledge, an over-the-counter market, the expected volatility of our common stock was developed using historical volatility for a peer group for a period equal to the expected term of the warrants. The fair value of the warrants will be significantly influenced by the fair value of our common stock, stock price volatility, and the risk-free interest components of the lattice technique.

Changes in the fair value of Derivative Liabilities, carried at fair value, are reported as “Change in fair value of derivative liability — warrants” in the Statement of Operations, and were as follows:

	For the Three Months Ended June 30,					For the Six Months Ended June 30,
	2017			2016		2017			2016
Warrants issued with Secured Convertible Notes	$	(17,500	)	$	103,084	$	90,000		$	178,671
Warrants issued with equipment financing leases		(1,750	)		10,308		9,000			17,862
Warrants issued with preemptive rights		(1,559	)		7,197		6,015			12,281
Warrants issued with 2015 private placement		(32,247	)		22,259		(3,419	)		22,541
Warrants issued with Bridge Financings		—			—		—			1,259
Total Derivative Gain (Loss)	$	(53,056	)	$	142,848	$	101,596		$	232,614

NOTE 6 – STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS

The following table summarizes the warrants outstanding at June 30, 2017, which are accounted for as equity instruments, all of which are exercisable:

Date Issued	Expiration Date	Exercise Price		Number of Warrants

7/1/2009	7/1/2019	$	8.00		6,000
10/8/2012	10/8/2027	$	12.00		5,000
12/14/2016	12/1/2023	$	8.00		50,000
					61,000

NOTE 7 – EQUITY INCENTIVE PLAN

We previously established the 2007 Stock Option Plan (the “2007 Plan”), which was scheduled to expire on October 30, 2017 and under which we granted key employees and directors options to purchase shares of our common stock at not less than fair market value as of the grant date. On May 4, 2017, the Board approved the 2017 Equity Incentive Plan (the “2017 Plan”) to replace the 2007 Stock Option Plan, which became effective upon the approval of the stockholders holding a majority of the voting power in the Company on July 18, 2017. The 2017 Plan replaces the 2007 Plan and authorizes us to issue awards (stock options and restricted stock) with respect of a maximum of 1,200,000 shares of our common stock, which equals the number of shares authorized under the 2007 Plan, as amended.

On July 24, 2017, certain stock options from the prior incentive stock option plan were cancelled and replacement stock options were awarded. The new stock option awards have an exercise price of $8 per share, a seven-year term, are vested to the same extent as the cancelled stock options, and are subject to certain other terms. The cancellation and reissuance of the stock options were treated as a modification under ASC 718, Compensation-Stock Compensation. The incremental value resulting from the modification, is estimated to be approximately $330,000, which will be recorded as compensation cost on the date of cancellation (for vested awards) or over the remaining requisite service period (for unvested awards).

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

The fair values of options granted are estimated on the dates of grant using the Black Scholes option-pricing model. As of June 30, 2017, 369,750 options to acquire shares have been granted cumulatively. Vesting of the options granted range from immediately to 20% per year, with most new options vesting on a straight-line basis over a four year period from the date issued. Rights to exercise the options that would have vested in any current service year vest immediately upon a change in control of the Company. The options expire at various dates through October 2023.

NOTE 8 – CAPITAL LEASES

As of June 30, 2017 and December 31, 2016, we have capital lease obligations as follows:

	June 30, 2017			December 31, 2016

Capital lease obligations	$	295,340		$	449,368
Unamortized warrant discount		(34,705	)		(65,595	)
Net obligations		260,635			383,773
Short-term portion of obligations		(200,768	)		(268,667	)
Long-term portion of obligations	$	59,867		$	115,106

Our AAOF capital lease obligations are four year leases starting on January 1, 2014 and January 1, 2015. Our other capital leases expire at various dates in 2018, have average effective interest rates of 0% and contain bargain purchase options that allow us to purchase the leased property for a minimal amount upon the expiration of the lease term.

NOTE 9 — Customer, Supplier, country, and Product Concentrations

Grants and Licensing Revenue Concentration

There was no grant revenue for the three months ended June 30, 2017. During the six months ended June 30, 2017, one grantor accounted for 94% of total grant revenue. During the three months ended June 30, 2016 and the six months ended June 30, 2016, one grantor accounted for 100% of the total grant revenue in each period. Our licensing revenue for the three months ended June 30, 2017 and 2016, and for the six months ended June 30, 2017 and 2016 came from one licensor.

Product Concentration

Concentrations of product sales greater than 10% of total product sales are shown in the table below. We attempt to minimize the risk associated with product concentrations by continuing to develop new products to add to our portfolio.

	For the Three Months Ended June 30,		For the Six Months Ended June 30,

	2017	2016	2017	2016
Grade C-300 HP	39%	*	24%	*
Grade C-500	*	*	15%	*
Grade C-750	*	11%	*	11%
Grade R-10	15%	14%	12%	12%
Grade M-15	*	*	*	16%
Grade M-25	*	10%	*	*

* Denotes less than 10% of product sales.

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

Customer Concentration

During the three months ended June 30, 2017 we had two customers whose purchases accounted for 34% and 24% of product sales. During the three months ended June 30, 2016 we had one customer who accounted for 30% of product sales.

For the six months ended June 30, 2017 we had two customers whose purchases accounted for 15%, and 11% of product sales. During the six months ended June 30, 2016 we had two customers whose purchases accounted for 17% and 15% of product sales.

At June 30, 2017, there were two customers who each had an accounts receivable balance greater than 10% of our total outstanding receivable balance. At June 30, 2016, there was only one customer who had an accounts receivable balance greater than 10% of our total outstanding receivable balance.

Country Concentration

We sell our products on a worldwide basis. All of these sales are denominated in U.S. dollars.

International sales for the three months ended June 30, 2017 were 50% of product sales as compared with 72% for the three months ended June 30, 2016. One country, China, accounted for 25% of product sales for the three months ended June 30, 2017 and one country, South Korea, accounted for 40% of product sales for the three months ended June 30, 2016.

International sales for the six months ended June 30, 2017 were 60% of product sales as compared with 74% for the six months ended June 30, 2016. Three countries, China, South Korea, and the United Kingdom accounted for approximately 15%, 16%, and 14%, respectively, of product sales for the six months ended June 30, 2017 and one country, South Korea, accounted for 37% of product sales for the six months ended June 30, 2016.

Suppliers

We buy raw materials used in manufacturing from several sources. These materials are available from a large number of sources. Thus, we believe a change in suppliers would have no material effect on our operations. We did not have any purchases from one supplier that were more than 10% of total purchases for the three months and six months ended June 30, 2017 and 2016.

NOTE 10 - RELATED PARTY TRANSACTIONS

We have a licensing agreement for exclusive use of patents and pending patents with Michigan State University (“MSU”), a shareholder of the Company via the MSU Foundation. During the three months ended June 30, 2017 and 2016 we recorded licensing expense of $12,500 per quarter. During the six months ended June 30, 2017 and 2016 we recorded licensing expense of $25,000 in each period.

We have also entered into product licensing agreements with, POSCO, a shareholder. See below for POSCO. Other than MSU and POSCO, there were no other royalty expenses or revenue recognized during the three or six months ended June 30, 2017 and 2016.

Beginning in 2014, POSCO, a licensee and shareholder of the Company, has had a contractual obligation to pay a minimum royalty of $100,000 per year to license certain technologies. This obligation is due annually on February 28 of the following year. We record this license revenue at a rate of $25,000 per quarter. POSCO is disputing its obligation to pay the minimum royalty and has not paid the royalty in any prior year. We filed a demand for arbitration in the International Court of Arbitration (ICA) on March 9, 2016 in an effort to resolve the dispute. The ICA has assigned an arbitrator, but no decision has been reached in the dispute. Allowances in the amounts of $175,000 and $150,000 were recorded at June 30, 2017 and December 31, 2016, respectively, to reflect an estimate of the portion of the 2017, 2016, 2015 and 2014 royalties that we believe may not be collectible. The accrued royalty and allowance are netted together and reflected in other current assets on the condensed consolidated balance sheet.

XG SCIENCES, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2017

On March 18, 2013, we entered into a series of agreements with two private investment funds: Aspen Advanced Opportunity Fund, LP (“AAOF”) and XGS II, LLC (“XGS II”), and pursuant to a Shareholders’ Agreement dated March 18, 2013 (as amended on February 26, 2016), a principal of each private fund serves as a member of our Board of Directors. These financing agreements were amended and restated on July 12, 2013 to provide for expanded financing commitments from AAOF and XGS II. Pursuant to these agreements, AAOF and XGS II agreed to provide $10 million of financing to the Company in the form of Secured Convertible Notes and AAOF agreed to provide an additional $1.0 million of lease financing arrangements. All of the principal and accrued interest on the Secured Convertible Notes issued to AAOF and XGS II were converted into Series A Preferred Stock in December 2016.

During the three months ended June 30, 2017 and 2016 we issued 7,140 shares per period of Series A Preferred stock to AAOF as payment for lease financing obligations under the terms of the Master Lease Agreement, dated March 18, 2013. For the six months ended June 30, 2017 and 2016 we issued a total of 14,280 shares per period as payment for lease obligations.

See also Note 3, the Dow Facility.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

In this Quarterly Report on Form 10-Q, unless otherwise indicated, the words “we”, “us”, “our”, “XG”, “XGS”, “XG Sciences” or the “Company” refer to XG Sciences, Inc. and its wholly owned subsidiary, XG Sciences IP, LLC, a Michigan limited liability company.

Introduction

The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements, and the notes thereto included herein. The information contained below includes statements of the Company’s or management’s beliefs, expectations, hopes, goals and plans that, if not historical, are forward-looking statements subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion on forward-looking statements, see the information set forth in the introductory note to this quarterly report on Form 10-Q under the caption “Forward-Looking Statements”, which information is incorporated herein by reference.

Overview of our Business

XG Sciences was formed in May 2006 for the purpose of commercializing certain technology to produce graphene nanoplatelets. First isolated and characterized in 2004, graphene is a single layer of carbon atoms configured in an atomic-scale honeycomb lattice. Among many noted properties, monolayer graphene is harder than diamonds, lighter than steel but significantly stronger, and conducts electricity better than copper. Graphene nanoplatelets are particles consisting of multiple layers of graphene. Graphene nanoplatelets have unique capabilities for energy storage, thermal conductivity, electrical conductivity, barrier properties, lubricity and the ability to impart physical property improvements when incorporated into plastics or other matrices.

We believe the unique properties of graphene and graphene nanoplatelets will enable numerous new product applications and the market for such products will quickly grow to be a significant market opportunity. Our business model is to design, manufacture and sell advanced materials we call xGnP^®graphene nanoplatelets and value-added products based on these nanoplatelets. We currently have hundreds of customers trialing our products for numerous applications, including, but not limited to lithium ion batteries, lead acid batteries, thermally conductive adhesives, composites, thermal transfer fluids, thermal management and heat transfer, inks and coatings, printed electronics, construction materials, cement, and military uses. We believe our proprietary processes have enabled us to be a low-cost producer of high quality, graphene nanoplatelets and value-added integrated products containing graphene nanoplatelets and that we are well positioned to address a wide range of end-use applications.

Our Customers

We sell products to customers around the world and have sold materials to over 1,000 customers in 47 countries since 2008. Some of these customers are research organizations and some are commercial organizations. Our customers have included well-known automotive and OEM suppliers around the world (Ford, Johnson Controls, Magna, Honda Engineering) world-scale lithium ion battery manufacturers in the US, South Korea and China (Samsung SDI, LG Chemical, Lishen, A123) and diverse specialty material companies (3M, BASF, Henkel, Dow Chemical, DuPont) as well as leading research centers such as Lawrence Livermore National Laboratory and Oakridge National Laboratory. We have also licensed some of our base manufacturing technology to other companies and we consider technology licensing a component of our business model. Our licensees include POSCO, the fourth largest steel manufacturer in the world by volume of output, and Cabot Corporation (“Cabot”), a leading global specialty chemicals and performance materials company. These licensees further extend our technology through their customer networks. Ultimately, we believe we will benefit in terms of royalties on sales of xGnP^® nanoplatelets produced and sold by our licensees. The below bar charts show the number of customers and total orders fulfilled by year based on actual purchases of our materials and orders for free samples or materials used in joint development programs.

Our Products

Bulk Materials. We target our xGnP^® nanoplatelets for use in a wide range of large and growing end-use markets. Our proprietary manufacturing processes allow us to produce nanoplatelets with varying performance characteristics that can be tuned to specific end-use applications based on customer requirements. We currently offer four commercial “grades” of bulk graphene nanoplatelet materials, each of which is available in various particle sizes, which allows for surface areas ranging from 50 to 800 square meters per gram of material depending on the product. Other grades may be made available, depending on the needs for specific applications. In addition, we sell our xGnP graphene nanoplatelets in the form of pre-dispersed mixtures with water, alcohol, or other organic solvents and resins. In addition to selling bulk nanoplatelets, we also offer the following integrated, value-added products that contain our graphene nanoplatelets in various forms.

Energy Storage Materials. These consist of specialty advanced materials that have been formulated for specific applications in the energy storage segment. Chief among these is our proprietary, specially formulated silicon-graphene composite material (also referred to as “SiG” or “XG SiG^®”) for use in lithium-ion battery anodes. XG SiG^® targets the never-ending need for higher battery capacity and longer life. In several customer trials, our SiG material has demonstrated the potential to increase battery energy storage capacity by 3-5x what is currently available with conventional lithium ion batteries today. Additionally, we offer various bulk materials for use as conductive additives for cathodes and anodes in lithium-ion batteries, as an additive to anode slurries for lead-carbon batteries, as a component in coatings for current collectors in lithium-ion batteries and we are investigating the use of our materials as part of other battery components.

Composites. These consist of an aqueous-based composition of specially designed xGnP® graphene nanoplatelets formulated to be easily dispersed in concrete and targeted specifically for consumer and industrial applications. Use of our GNP® Concrete Additive in cement mixtures results in improved barrier resistance, durability, toughness and corrosion protection. The graphene nanoplatelets promote the formation of more uniform and smaller grain structure in the cement. This fine-grain and uniform structure gives concrete improvements in flexural and compressive strength. In addition, the embedded graphene nanoplatelets will stop cracks from forming and retard crack propagation, should any cracks form – the combination of which will improve lifetime and durability. We intend to further extend our integrated composites portfolio to include pre-compounded resins derived from a range of thermoplastics as well as mother batches of resins and xGnP® nanoplatelets and their combination with resins and fibers for use various end-use applications. In addition we offer various bulk materials with demonstrated efficacy in plastic composites to impart improved physical performance to such matrices.

Thermal Management Materials. These consist mainly of two types of products, our XG Leaf^® sheet products and various thermal interface materials (“TIM”) in the form of custom greases or pastes. XG Leaf^® is a family of sheet products ideally suited for use in thermal management in portable electronics, which may include cell phones, tablets and notebook PC’s. As these devices continue to adopt faster electronics, higher data management capabilities, brighter displays with ever increasing definition, they generate more and more heat. Managing that heat is a key requirement for the portable electronics market and our XG Leaf^® product line is well suited to address the need. These sheets are made using special formulations of xGnP^® graphene nanoplatelets as precursors, along with other materials for specific applications. There are several different types of XG Leaf^® available in various thicknesses, depending on the end-use requirements for thermal conductivity, electrical conductivity, or resistive heating. Our custom TIM greases and pastes are also designed to be used in various high temperature environments. Additionally, we offer various bulk materials for use as active components in liquids, coatings and plastic composites to impart improved thermal management performance to such matrices.

Inks and Coatings. These consist of specially-formulated dispersions of xGnP^®together with solvents, binders, and other additives to make electrically or thermally conductive products designed for printing or coating and which are showing promise in diverse customer applications such as advanced packaging, electrostatic dissipation and thermal management. We also offer a set of standardized ink formulations suitable for printing. These inks offer the capability to print electrical circuits or antennas, or might be suitable for other electrical or thermal applications. All of these formulations can be customized for specific customer requirements.

Our Focus Areas

We believe we are a “platform play” in advanced materials, because our proprietary processes allow us to produce varying grades of graphene nanoplatelets that can be mapped to a variety of applications in many market segments. However, we are prioritizing our efforts in specific areas and with specific customers that we believe represent opportunities for either relatively near-term revenue or especially large and attractive markets. At this time, we are focused on three high priority areas: Energy Storage, Thermal Management and Composites. The following table shows examples of the types of applications we are pursuing, the expecting timing of revenue and the addressable market size of selected market opportunities.

XGS Market/Application Focus Areas & 2018 Market Size

(table)

(1)	Avicenne Energy, “The Worldwide Rechargeable Battery Market 2014 – 2025”, 24^th Edition — V3, July 2015.

(2)	Avicenne Energy, “The Worldwide Rechargeable Battery Market 2014 – 2025”, 24^th Edition — V3, July 2015 & Internal Estimates.

(3)	ArcActive via Nanalyze, April 3, 2015.

(4)	ArcActive via Nanalyze, April 3, 2015 & Internal Estimates.

(5)	Future Markets Insights, “Consumer Electronics Market: Global Industry Analysis and opportunity Assessment 2015 – 2020”, May 8, 2015.

(6)	Prismark, “Market Assessment: Thin Carbon-Based Heat Spreaders”, August 2014.

(7)	Reporterlink.com, “Semiconductor & IC Packaging Materials Market…”, May 2014.

(8)	Prismark, 2015.

(9)	Grand View Research, “Global Plastics Market Analysis…”, August 2014.

(10)	From (9) and internal estimates: 2018 = 305 million tons of plastic, if 10% of the market adopted xGnP to enhance their properties, and at only 1% by weight as an additive, then in 2018 305,000 tons or 305,000,000 kilos of xGnP would be required. At $30 a Kg - the value is $9.1 Bn per year.

Commercialization Process

Because graphene is a new material, most of our customers are still developing applications that use our products. Commercialization is a process, the exact timing of which is often difficult to predict. It starts with our own internal R&D to validate performance for an identified market or customer-specific need. Our customers then validate the performance of our materials and determine whether our products can be incorporated into their manufacturing processes. This is initially done at the pilot scale. Our customers then have to introduce products that incorporate our materials to their own customers to validate performance. After their customers have validated performance, our customers will then move to commercial scale production. Every customer goes through the same process, but will do so at varying speeds, depending on the customer, the product and the end-use market. Thus, we are not always able to predict when our customers will begin ordering commercial volumes of our materials or their expected volumes over time. However, as customers move through the process, we generally receive feedback and gain greater insights regarding their commercialization plans. The following are examples of where our products are providing value to our customers at levels that we believe will warrant their use on a commercial basis (see also Exhibit 99.1 to Post-Effective Amendment No. 5 to the Existing Registration Statement for our Summary Customer Pipeline validating the value of our products in various end-use markets and applications):

●

Lead acid battery manufacturer demonstrating approximately 90% improvement in measured cycle life, appreciable improvement in capacity and charge acceptance and without any loss in water retention performance, and

●

Light emitting diode module and product company demonstrated approximately 50% improvement in thermal management capability when compared to existing commercial thermal management products, translating into a 15% improvement in thermal management at the device level, and

●

Automotive parts supplier demonstrating improvements in thermal stability for polymer composites incorporating our materials, allowing for approximately 20% higher operating temperatures and a 50% improvement in strength at the elevated temperature, and

●

Industrial refrigeration equipment supplier demonstrating improved heat transfer efficiency and energy savings when our xGnP^® graphene nanoplatelets are incorporated as a component in the thermal-transfer fluids, and

●

Construction company demonstrating less than one weight percent of our product in construction material composites improves flexural strength by more than 30%, and

●

Plastics composite part manufacturer demonstrating 7-30% improvement in strength and 40% improvement in modulus when used in sheet molding compound, and

●

Engineering design firm for automotive manufacturers found approximately 20% reduction in operating temperature and in thermal uniformity when XG Leaf^®replaces standard cooling fins in lithium ion battery packs, and

●

Plastic composite parts manufacturer demonstrating 25% increase in tensile strength and 15% improvement in flex modulus for high-density polyethylene composite.

The process of “designing-in” new materials is relatively complex and involves the use of relatively small amounts of the new material in laboratory and engineering development for an extended period of time. Following successful development, customers that incorporate our materials into their products will then order much larger quantities of material to support commercial production. Although our customers are under no obligation to report to us on the usage of our materials, some have indicated that they have introduced or will soon introduce commercial products that use our materials. Thus, while many of our customers are currently purchasing our materials in kilogram (one or two pound) quantities, some are now ordering at ton quantities and we believe many will require tens of tons or even hundreds of tons of material when they commercialize products that incorporate our materials. We also believe that those customers already in production will increase their order volume as demand increases and others will begin to move into commercial volume production as they gain more experience in working with our materials and engage new customers. For example, we shipped a 1 metric ton order in Q4 2016 to a customer who is currently moving into larger scale production and had previously used smaller quantities. In the first quarter of 2017 we shipped 1.6 metric tons of dry powder for various end-use customers and another 1.8 metric tons in the second quarter. As our customers ramp production, we have known customer demand of 15 metric tons of product in the second half of 2017 with upside to about 20 metric tons. This demand profile is further evidence that we are transitioning into a higher-volume production mode, and we expect further, sizable increases into 2018.

We have been reporting average order size as a further indicator of commercial traction. The majority of our customers are still ordering in smaller quantities consistent with their development and engineering qualification work. The average order sizes, by quarter from Q1 2015 through Q2 2017 are given below. These data represent orders shipped in the respective quarter and exclude no charge orders targeted mainly for R&D purposes. The data show that the average order size has increased steadily over the last two years, and we believe that it will continue to increase in the second half of 2017 and in 2018 as more customers commercialize products using our materials.

(table)

2017 and 2018 Revenue

We are tracking the commercial and development status of more than 100 different customer applications using our materials with some customers pursuing multiple applications. As of June 30, 2017, we had fourteen specific customer applications where our materials are incorporated into our customer’s products and such customers are actively promoting or selling these products to their customers. In addition, we have another eleven customer applications where our customers have indicated that they expect to begin shipping product incorporating our materials in the next 3 – 6 months, and we have another sixteen customer applications where our customers have indicated intent to commercialize in the next 6 – 9 months. We also have numerous additional customers with whom we are working that have not yet indicated an exact date for commercialization, but we believe have the potential to contribute to revenue in 2018. The following graphic demonstrates the trend over the past 5 quarters as an increasing number of customers indicate their intent to commercialize and move into actively selling or promoting products for future sales. We anticipate that the average order size for these customers will increase in the second half of 2017 and 2018 as their demand grows. As a result, we believe we will begin shipping significantly greater quantities of our products, and thus begin scaling revenue in the second half 2017 and 2018. Based on the status of current discussions with customers and their feedback on the performance of our materials in their products, we believe we will exit 2017 with a greater than $5 million annualized revenue run rate, and we will be able to recognize approximately $15 – $30 million of revenue in 2018.

(table)

(a)

Customer applications where our materials are used in customer products and they are actively promoting or selling them to their customers.

(b)

Customer applications where our customers are indicating that they expect to begin shipping products incorporating our materials in the next 3-6 months.

(c)

Customer applications where our customers are indicating an intent to commercialize in the next 6-9 months.

Additional 10’s of customers demonstrating efficacy and moving through qualification process.

Addressable Markets

The markets that we serve are large and rapidly growing. For example, as shown in the figure below, Avicenne Energy (“The Rechargeable Battery Market, 2014 – 2025”, July 2015) estimates that the market for materials used in lithium ion battery anodes is currently approximately $1 billion, but is expected to approximately double over the next ten years. We believe our ability to address next generation anode materials represents a significant opportunity for us.

(table)

According to Prismark Partners, LLC, a leading electronics industry consulting firm specializing in advanced materials, the 2014 market for finished graphitic heat spreaders as sold to the OEM and EMS companies with adhesive, PET, and/or copper backing for selected portable applications was $600 million, and is expected to reach $900 million in 2018. The market is currently in a significant expansion period driven by the demand for portable devices. In a press release dated June 30, 2016, Gartner, Inc., a leading research organization, estimated the 2016 global smartphone market at 1.9 billion units and worldwide combined shipments of devices (PC’s, tablets, ultraphones and mobile devices are expected to reach 2.4 billion units in 2016). Every cell phone has some form of thermal management system, and we believe many of the new smart phones and other portable devices being developed can benefit from the thermal management properties of our XG Leaf^® product line. In August 2016, International Data Corporation (IDC) in their Worldwide Quarterly Tablet Tracker, estimated the global shipment of tablets in 2016 at 183.4 million units. Thus, we believe our XG Leaf^® product line is well positioned to address a very large and rapidly growing market.

Our Intellectual Property

Some of our proprietary manufacturing processes were developed at Michigan State University (MSU) and licensed to us in 2006. We licensed three U.S. patents and patent applications from MSU. However, over time, our scientists and engineers have made many further discoveries and inventions that are embodied in the form of (and as of June 30, 2017): six additional U.S. patents, three China patents, one Taiwan patent, one European patent, one Japan patent, 16 additional U.S. patent applications, and numerous trade secrets. For each patent application filed in the U.S., we make a determination on the nature and value of the patent. For many of the applications filed in the U.S., additional filings are made in other countries such as the European Union, Japan, South Korea, China, Taiwan or other applicable countries. As of June 30, 2017, we maintain 36 international patent applications. These filings and analyses are made on a case-by-case basis. Typically, patents that are defensive in nature are not filed abroad, while those that are protective of active XGS products or applications are filed in relevant countries abroad. Our general IP strategy is to keep as trade secrets those manufacturing processes that are difficult to enforce should they be disclosed and to seek patent coverage for other manufacturing processes, materials derived from those processes, unique combinations of materials and end uses of materials containing graphene nanoplatelets. We believe that the combination of our rights under the MSU license, our patents and patent applications, and our trade secrets create a strong intellectual property position.

Operating Segment

We have one reportable operating segment that manufactures xGnP^® graphene nanoplatelets and value-added products produced therefrom, conducts research on graphene nanoplatelets and related products, and licenses our technology as appropriate. As of June 30, 2017, we shipped products on a worldwide basis, but all of our assets were located within the United States.

Results of Operations for the Three and Six Months Ended June 30, 2017 Compared with the Three and Six Months Ended June 30, 2016

Summary Income Statement	For the Three Months Ended June 30,									For the Six Months Ended June 30,
	2017			2016			Change			2017			2016			Change
Total Revenue	$	284,079		$	244,090		$	39,989		$	566,268		$	350,142		$	216,126
Cost of Goods Sold		508,694			429,252			79,442			996,614			804,999			191,615
Gross Loss		(224,615	)		(185,162	)		(39,453	)		(430,346	)		(454,857	)		24,511
Research & Development Expense		227,062			419,007			(191,945	)		490,626			635,357			(144,731	)
Sales, General & Administrative Expense		923,765			625,381			298,384			1,920,352			1,721,603			198,749
Total Operating Expense		1,150,827			1,044,388			106,439			2,410,978			2,356,960			54,018
Operating Loss		(1,375,442	)		(1,299,550	)		(145,892	)		(2,841,324	)		(2,811,817	)		(29,507	)
Other Income (Expense)		(181,501	)		65,725			(247,226	)		(85,961	)		95,840			(181,801	)
Net Loss	$	(1,566,943	)	$	(1,163,825	)	$	(393,118	)	$	(2,927,285	)	$	(2,715,977	)	$	(211,308	)

Revenue

Revenue for the three and six months ended June 30, 2017 and 2016, by category, are shown below.

Summary of Revenue	For the Three Months Ended June 30,							For the Six Months Ended June 30,
	2017		2016		Change			2017		2016		Change
Product Sales	$	259,079	$	82,035	$	177,044		$	416,779	$	141,777	$	275,002
Grants		—		137,055		(137,055	)		99,489		158,365		(58,876	)
Licensing		25,000		25,000		—			50,000		50,000		—
Net Loss	$	284,079	$	244,090	$	39,989		$	566,268	$	350,142	$	216,126

Product sales consist of two broad categories: (1) material sold to customers for research or development purposes; and (2) production orders for customers. Typically, the order sizes for the first category are relatively small, however we expect orders in the second category to be much larger in the future. For the three months ended June 30, 2017, product sales increased by $177,044, or 216% from the comparable period in the prior year. For the six months ended June 30, 2017, product sales increased by $275,002, or 194% from the comparable period in the prior year. The main reason for the increase was customers moving through development programs towards commercialization, requiring larger quantities of our materials for advanced testing, pilot production and commercial-scale production activities. We believe that those customers already in production will increase their order volume as demand increases and others will begin to move into commercial volume production as they gain more experience in working with our materials and engage their own customers. As a result of this movement, we shipped 1.6 metric tons of bulk powders in the first quarter of 2017, 1.8 metric tons of bulk powders in the second quarter of 2017, and we expect to ship 15 to 20 metric tons of bulk powders in the second half of 2017.

We ship our products from our Lansing, MI manufacturing facilities to customers around the world. During the three months ended June 30, 2017, we shipped materials to customers in 19 countries, as compared to 15 countries during the same three month period in 2016. During the first six months ended June 30, 2017, we shipped materials to customers in 25 different countries, versus 21 countries in 2016. For the three months ended, June 30, 2017 and 2016, shipments to only one country accounted for more than 10% of product sales, China and South Korea, respectively. Shipments to three countries other than the United States accounted for more than 10% of product sales during the first six months ended June 30, 2017 and only one country in 2016. Those countries, China, South Korea and the United Kingdom accounted for approximately 46% of total product sales during the first six months ended June 30, 2017 and South Korea accounted for 37% of total product sales during the first six months ended June 30, 2016.

Order Summary

The table below shows a comparison of domestic and international orders fulfilled (note that this does not include orders for free samples). The table also includes the average order size for product sales. These numbers indicate that our customer base remains active with research and development projects that use our materials and the breadth of our geographic coverage. The average order size for the product revenue during the first six months ended June 30, 2017 increased by 164% as compared to the same period in 2016. Although the average size of these orders is still relatively small, we have begun shipping in metric ton quantities to multiple customers.

Order Summary	For the Three Months Ended June 30,							For the Six Months Ended June 30,
	2017		2016		Change			2017		2016		Change

Number of orders - domestic		36		23		13			66		51		15
Number of orders - international		42		39		3			83		83		0
Number of orders - total		78		62		16			149		134		15
Average order size for product sales recorded in our Statement of Operations	$	3,322	$	1,323	$	1,998		$	2,797	$	1,058	$	1,739
% change						151	%						164	%

Grant Revenue

Grant revenue for the three and six months June 30, 2017 and 2016 consisted of proceeds from sources as shown in the table below:

	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2017					2016					2017					2016
			% of Revenue					% of Revenue					% of Revenue					% of Revenue
US Department of Energy	$	—		0	%	$	137,055		100	%	$	93,747		94	%	$	158,365		100	%
Daimler / University of Michigan		—		0	%		—		0	%		5,742		6	%		—		0	%
Total	$	—		0	%	$	137,055		100	%	$	99,489		100	%	$	158,365		100	%

Licensing Revenue

Licensing revenues during the three and six months ended June 30, 2017 and 2016 were accrued based on minimum royalty payments from a license to certain of the Company’s technology granted in 2011, which stipulates a minimum of $100,000 in royalties are due starting in 2014 and annually thereafter. These revenues are being accrued at the rate of $25,000 per quarter. However, a dispute has arisen regarding interpretation of the licensing agreement, so we reserved half of these revenues as a potential bad debt. This expense is included in selling, general, and administrative expenses. The net amount, $12,500 per quarter is the net result included in our statement of operations.

Cost of Goods Sold

We use a standard cost system to estimate the direct costs of products sold. Direct costs include estimates of raw material costs, packaging, freight charges net of those billed to customers, and an allocation for direct labor and manufacturing overhead. Because of the nature of our production processes, there is a substantial fixed manufacturing expense requirement that represents the ongoing cost of maintaining production facilities that are not directly related to products sold, so we use a “full capacity” allocation of overhead based on an estimate of what product costs would be if the manufacturing facilities were operating on a full-time basis and producing products at the designed capacity. This estimate involves estimating both the level of expenses as well as production amounts as if the manufacturing facility were operating on a continuous 24 hour per day, 5 day per week production schedule.

Gross Profit Summary

The following table shows the relationship of direct costs to product sales for the three and six months ended June 30, 2017 and 2016:

Gross Profit Summary	For the Three Months Ended June 30,								For the Six Months Ended June 30,
	2017			2016			Change		2017			2016			Change

Product Sales	$	259,079		$	82,035		$	177,044	$	416,779		$	141,777		$	275,002
Direct Costs		93,542			25,020			68,522		210,312			57,052			153,260
Direct Cost Margin	$	165,537		$	57,015		$	108,522	$	206,467		$	84,725		$	121,742
% of Sales		63.9	%		69.5	%				49.5	%		59.8	%
Unallocated Manufacturing Expense		415,152			404,232			10,920		786,302			747,947			38,355
Gross Loss on Product Sales	$	(249,615	)	$	(347,217	)	$	97,602	$	(579,835	)	$	(663,222	)	$	83,387

We believe that the fluctuations in gross loss on product sales and direct cost from period to period are not indicative of future margins because of the relatively small size of our sales in comparison to our future expectations. Direct costs vary depending on the size of an order, the specific products being ordered, and other factors like shipping destination (which on small orders can represent a significant percentage of the cost).

Costs associated with grant revenue tend to be a mixture of facilities use, management time, labor from scientists, technicians and manufacturing personnel, and some supplies. Because of the difficulty of developing and maintaining an administrative system to gather direct costs for grants, together with the relatively small size of grant revenue, we do not track direct costs for grant revenue as a separate cost category. Therefore, we do not calculate direct cost margins associated with grant revenue but, rather, we view this revenue as being supported by indirect corporate expenses.

Costs associated with licensing revenue tend to be a mixture of IP costs as well as management and administrative expenses that are indirect in nature. As such, we do not assign direct costs to licensing revenue. Where revenue from a license agreement can be assigned to specific product revenue, we classify this revenue as product sales and, using our standard cost system, assign direct costs to those sales.

The remaining “non-direct” costs of operating our manufacturing facilities are recorded as unallocated manufacturing expenses. These expenses include personnel costs, rent, utilities, indirect supplies, depreciation, and related indirect expenses. Unallocated manufacturing expenses are expensed as incurred. We allocate these costs to direct product costs based on the proportion of these expenses that would be representative direct product costs if we were operating our factory at full capacity.

For the three months ended June 30, 2017, unallocated manufacturing expenses increased by 3% to $415,152 as compared to $404,231 during the same period in 2016, an increase of $10,920. Higher levels of manufacturing overhead expense will be incurred as we prepare for anticipated volume increases.

For the six months ended June 30, 2017, unallocated manufacturing expenses increased by 5% to $786,302 as compared to $747,947 during the same period in 2016, an increase of $38,355. In the first two quarters of 2017 we have incurred some higher levels of manufacturing overhead expense as we prepare for anticipated volume increases.

Sales, General and Administrative Expenses

During the three months ended June 30, 2017 we incurred selling, general and administrative expenses (SGA) of $923,765. This is an increase of $298,383 or 48% from the same period in 2016. During the three months ended June 30, 2016, we incurred $182,146 for inter-departmental charges that were expensed to the Research and Development cost center for time and charges related to the DOE Phase I SBIR grant. This resulted in a reduction of SGA expenses in 2016 that did not occur in 2017. As we continue to grow and gain traction in the marketplace our SGA expenses will fluctuate but should stabilize and become more fixed in nature as we achieve economies of scale.

During the six months ended June 30, 2017 we incurred selling, general and administrative expenses (SGA) of $1,920,352. This is an increase of approximately $198,749 or 12% from the same period in 2016. During the six months ended June 30, 2016, we incurred $188,896 for inter-departmental charges that were expensed to the Research and Development cost center for time and charges related to the DOE Phase I SBIR grant. This resulted in a reduction of SGA expenses in 2016 that did not occur in 2017. As we continue to grow and gain traction in the marketplace our SGA expenses will fluctuate but should stabilize and become more fixed in nature as we achieve economies of scale.

Research and Development Expenses

Research and Development expenses for the three months ended June 30, 2017 were $227,062 as compared to $419,007 for the same period in 2016. The decrease of $191,944 or 46% is largely due to higher expenses in 2016 to work on and complete the DOE Phase I SBIR grant (which was completed by June 30, 2016).

Research and Development expenses for the six months ended June 30, 2017 were $490,626 as compared to $635,357 for the same period ended June 30, 2016. The decrease of $144,731 or 23% is largely due to higher expenses in 2016 to work on and complete the DOE Phase I SBIR grant.

Other Income (Expense)

The following table shows a comparison of other income and expense by major component for the three and six months ended June 30, 2017 and 2016:

Other Income (Expense)	For the Three Months Ended June 30,									For the Six Months Ended June 30,
	2017			2016			Change			2017			2016			Change
Interest expense, net	$	(54,445	)	$	(101,123	)	$	46,678		$	(113,533	)	$	(184,774	)	$	71,241
Gain (loss) from change in fair value of derivative liability - warrants		(53,056	)		142,848			(195,904	)		101,596			232,614			(131,018	)
Gov’t incentives, net		(74,000	)		24,000			(98,000	)		(74,024	)		48,000			(122,024	)
Total	$	(181,501	)	$	65,725		$	(247,226	)	$	(85,961	)	$	95,840		$	(181,801	)

Interest expense, net of interest income in the three and six month periods ending June 30, 2017, decreased by $46,678 and $71,241, respectively from the comparable periods in the prior year as a result of paying down the balance on our lease financing arrangements.

Gain/(loss) from changes in the fair value of derivative liability warrants from the previous valuation period are characterized as other (expense)/other income on our Statement of Operations as a result of the GAAP requirement to use variable accounting for such instruments. These values fluctuate from period to period as a result of updating inputs used in the trinomial lattice model used to value such warrants, including risk free rate, volatility, remaining term of each warrant, and the underlying stock price assumption used in such calculations.

Government incentives include accruals for incentive awards from state and local government entities relating to new hires during the period indicated, net of any true up of previous accruals to reflect actual payments. In 2016, we accrued $74,000 of such accruals for expected incentive awards from the Michigan Economic Growth Authority (“MEGA”), based on our experience in receiving such incentive awards over the previous four years for our hiring practices. Upon review by MEGA in May 2017, our 2016 incentive was declined, because of our failure to meet a baseline assumed hiring threshold, which we missed by two full-time equivalent employees by December 31, 2016. Since 2016 was the final year for this incentive award program, we wrote off this previously accrued award in the three months ended June 30, 2017.

Cash Flow Summary

The following condensed cash flow statement compares cash flow from operating, investing, and financing activities for the six months ended June 30, 2017 and 2016.

	For the Six Months Ended June 30,						Change 2016 – 2017
	2017			2016			$			%
Cash, beginning of period	$	1,785,343		$	1,060,224		$	725,119			68	%
Net Cash provided by (used in):
Operating activities		(2,384,760	)		(1,777,826	)		(606,934	)		34
Investing Activities		(446,626	)		(92,961	)		(353,665	)		380
Financing Activities		1,477,150			1,770,350			(293,200	)		(17	)
Net increase (decrease) in cash		(1,354,236	)		(100,437	)		(1,253,799	)		1248
Cash, end of period	$	431,107		$	959,787		$	(528,680	)		(55	)%

Net cash used in operating activities for the six months ended June 30, 2017 and 2016 was $2,384,760 and $1,777,826, respectively. The increase of 34% or $606,934 is largely attributable to current year initiatives to pay down and keep current on accounts payable and other liabilities.

Investing activities for the six months ended June 30, 2017 included net capital expenditures for the purchase of property and equipment of $352,003 and $94,623 for intellectual property as compared with $39,314 for property and equipment and $53,647 for intellectual property during the same period in 2016. These levels of capital expenditures are higher as we have begun to update and install equipment necessary to increase production capacity to meet anticipated customer orders for those customers who are moving into commercialization of products containing our materials.

Financing activities provided a net increase in cash of $1,477,150 and $1,770,350 for the six months ended June 30, 2017 and 2016, respectively. For the first six months ended June 30, 2017 gross proceeds from the issuance of common stock was $1,720,400 and stock issuance expenses were $233,500 as compared to proceeds from the issuance of common stock as of June 30, 2016 of $2,285,032 and stock issuance expenses of $336,600.

Liquidity and Capital Expenditures

As of July 31, 2017, we had cash on hand of $1,000,702, and currently available funds of $2 million under the Dow Facility, which we believe will fund our operations for at least the next 12 months. We also have a commitment from a shareholder group, dated March 27, 2017, to provide up to $1 million of additional equity capital in the event we are unable to raise such funds from third party investors through the sale of our common stock in the IPO. Our financial projections show that we may need to raise an additional $15 million or more before we are capable of achieving sustainable free cash flow after capital expenditures. We intend that the primary means for raising such funds will be through our IPO, the additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital in the period after October 31, 2016. Thus far, we have raised $2.6 million through the sale of 323,578 shares of common stock between November 1, 2016 and June 30, 2017 towards the requirement to raise $10 million of additional equity capital in order to open up the remaining $5 million of availability on the Dow Facility. There can be no assurance that we will be able to raise additional equity capital in the IPO or in subsequent equity offerings or that the terms and conditions of any future financings will be workable or acceptable to us and our stockholders.

Critical Accounting Estimates

In preparing the condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our Form 10-K for the year ended December 31, 2016.

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, fair valued liabilities, sales returns and discounts, and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various judgements about the reported values of assets, liabilities, revenue and expenses. Actual results may materially differ from these estimates.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Smaller reporting companies are not required to provide this information.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by SEC Rule 15d-15, our management carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report.

(b) Changes in internal controls. There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

Since 2014, POSCO, a shareholder and licensee of certain technology, has had a contractual obligation to pay us a minimum royalty of $100,000 per year as consideration for our license agreement. This obligation is due annually on February 28 of the following year. We record this license revenue at a rate of $25,000 per quarter. POSCO is disputing its obligation to pay the minimum royalty and has not paid the royalty in any prior years. We filed a demand for arbitration in the International Court of Arbitration (ICA) on March 9, 2016 in an effort to resolve the dispute. The ICA has assigned an arbitrator, but no decision has been reached in the dispute.

Item 1A. Risk Factors.

Smaller reporting companies are not required to provide this information.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None

Item 6. Exhibits.

EXHIBIT NUMBER	DESCRIPTION	LOCATION

10.1	Updated Form of Subscription Agreement for Primary Offering	Incorporated by reference to the Company’s Form S-1, as amended, filed with the SEC on April 13, 2017

10.3	2017 Equity Incentive Plan	Incorporated by reference to the Company’s current report on Form 8-K filed with the SEC on July 25, 2017

31.1	Certifications of the Chief Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith

32.1	Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002*	Filed herewith

101. INS	XBRL Instance Document	Filed herewith

101. CAL	XBRL Taxonomy Extension Calculation Link base Document	Filed herewith

101. DEF	XBRL Taxonomy Extension Definition Link base Document	Filed herewith

101. LAB	XBRL Taxonomy Label Link base Document	Filed herewith

101. PRE	XBRL Extension Presentation Link base Document	Filed herewith

101. SCH	XBRL Taxonomy Extension Scheme Document	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

XG SCIENCES, INC.

Dated: August 11, 2017	By:	/s/ Philip L. Rose
	Name:	Philip L. Rose
	Title:	Chief Executive Officer, President, Treasurer, Principal Executive Officer and Principal Financial Officer

Dated: August 11, 2017	By:	/s/ Corinne Lyon
	Name:	Corinne Lyon
	Title:	Controller and Principal Accounting Officer

EX-31.1 2 s107106_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Philip L. Rose, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of XG Sciences, Inc. for the period ended June 30, 2017;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)

designed such disclosure controls and procedures, or have caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

DATE: August 11, 2017

By: /s/Philip L. Rose

Name: Philip L. Rose

Titles: Chief Executive Officer, President,
Treasurer, Principal Executive Officer and
Principal Financial Officer

EX-32.1 3 s107106_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of XG Sciences, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philip L. Rose, Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

DATE: August 11, 2017

	By:/s/ Philip L. Rose
	Name: Philip L. Rose
	Titles: Chief Executive Officer, President, Treasurer, Principal Executive Officer and Principal Financial Officer

GRAPHIC 4 img001_v1.jpg GRAPHIC begin 644 img001_v1.jpg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end GRAPHIC 5 img002_v1.jpg GRAPHIC begin 644 img002_v1.jpg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end GRAPHIC 6 img003_v1.jpg GRAPHIC begin 644 img003_v1.jpg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img004_v1.jpg GRAPHIC begin 644 img004_v1.jpg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img005_v1.jpg GRAPHIC begin 644 img005_v1.jpg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end GRAPHIC 9 img006_v1.jpg GRAPHIC begin 644 img006_v1.jpg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end EX-101.INS 10 cik0001435375-20170630.xml XBRL INSTANCE FILE 0001435375 2017-01-01 2017-06-30 0001435375 2017-08-11 0001435375 2017-06-30 0001435375 cik0001435375:TheDowChemicalCompanyMember 2017-01-01 2017-06-30 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember 2016-12-01 2016-12-31 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember 2016-12-31 0001435375 us-gaap:SubsequentEventMember cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember 2017-07-17 2017-07-18 0001435375 2016-11-01 2017-06-30 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember cik0001435375:Warrant1Member 2016-12-01 2016-12-31 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember cik0001435375:Warrant1Member 2016-12-31 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember cik0001435375:Warrant1Member 2016-01-01 2016-12-31 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember cik0001435375:Warrant1Member 2017-06-30 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember cik0001435375:Warrant1Member 2017-01-01 2017-06-30 0001435375 cik0001435375:DrawLoanNoteAndAgreementMember cik0001435375:TheDowChemicalCompanyMember us-gaap:SecuredDebtMember 2017-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2015-04-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:SeriesBPreferredStockMember 2015-04-01 2016-12-31 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2016-02-24 2016-02-25 0001435375 us-gaap:PrivatePlacementMember us-gaap:SeriesBPreferredStockMember us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2017-01-01 2017-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:SeriesBPreferredStockMember 2016-01-01 2016-12-31 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2017-06-30 0001435375 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember 2017-06-30 0001435375 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember 2017-01-01 2017-06-30 0001435375 us-gaap:CapitalLeaseObligationsMember us-gaap:WarrantMember 2017-01-01 2017-06-30 0001435375 us-gaap:CapitalLeaseObligationsMember us-gaap:WarrantMember 2017-06-30 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember us-gaap:WarrantMember 2017-01-01 2017-06-30 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember us-gaap:WarrantMember 2017-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember cik0001435375:ExistingStockholdersMember 2017-01-01 2017-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember cik0001435375:ExistingStockholdersMember 2017-06-30 0001435375 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001435375 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember 2016-12-31 0001435375 us-gaap:CapitalLeaseObligationsMember us-gaap:WarrantMember 2016-12-31 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember 2017-06-30 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember 2016-12-31 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2016-12-31 0001435375 2016-12-31 0001435375 us-gaap:MinimumMember 2017-01-01 2017-06-30 0001435375 us-gaap:MaximumMember 2017-01-01 2017-06-30 0001435375 us-gaap:MinimumMember 2017-06-30 0001435375 us-gaap:MaximumMember 2017-06-30 0001435375 us-gaap:MinimumMember 2016-01-01 2016-12-31 0001435375 us-gaap:MaximumMember 2016-01-01 2016-12-31 0001435375 us-gaap:MinimumMember 2016-12-31 0001435375 us-gaap:MaximumMember 2016-12-31 0001435375 2016-01-01 2016-12-31 0001435375 us-gaap:BridgeLoanMember us-gaap:InvestorMember cik0001435375:Warrant1Member 2017-01-01 2017-06-30 0001435375 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember 2016-01-01 2016-06-30 0001435375 us-gaap:CapitalLeaseObligationsMember us-gaap:WarrantMember 2016-01-01 2016-06-30 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember us-gaap:WarrantMember 2016-01-01 2016-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2016-01-01 2016-06-30 0001435375 us-gaap:BridgeLoanMember us-gaap:InvestorMember cik0001435375:Warrant1Member 2016-01-01 2016-06-30 0001435375 2016-01-01 2016-06-30 0001435375 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember 2017-04-01 2017-06-30 0001435375 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember 2016-04-01 2016-06-30 0001435375 us-gaap:CapitalLeaseObligationsMember us-gaap:WarrantMember 2017-04-01 2017-06-30 0001435375 us-gaap:CapitalLeaseObligationsMember us-gaap:WarrantMember 2016-04-01 2016-06-30 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember us-gaap:WarrantMember 2017-04-01 2017-06-30 0001435375 cik0001435375:FinancingAgreementsMember cik0001435375:PreemptiveRightsOfferingMember us-gaap:ConvertiblePreferredStockMember us-gaap:WarrantMember 2016-04-01 2016-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2017-04-01 2017-06-30 0001435375 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2016-04-01 2016-06-30 0001435375 us-gaap:BridgeLoanMember us-gaap:InvestorMember cik0001435375:Warrant1Member 2017-04-01 2017-06-30 0001435375 us-gaap:BridgeLoanMember us-gaap:InvestorMember cik0001435375:Warrant1Member 2016-04-01 2016-06-30 0001435375 2017-04-01 2017-06-30 0001435375 2016-04-01 2016-06-30 0001435375 us-gaap:WarrantMember cik0001435375:PreemptiveRightsOfferingMember 2017-01-01 2017-06-30 0001435375 us-gaap:WarrantMember 2017-06-30 0001435375 cik0001435375:Warrant1Member 2017-01-01 2017-06-30 0001435375 cik0001435375:Warrant1Member 2017-06-30 0001435375 cik0001435375:Warrant2Member 2017-01-01 2017-06-30 0001435375 cik0001435375:Warrant2Member 2017-06-30 0001435375 cik0001435375:IncentiveStockOptionPlanMember 2017-01-01 2017-06-30 0001435375 cik0001435375:StockOptionPlan2007Member us-gaap:MaximumMember 2017-06-30 0001435375 cik0001435375:StockOptionPlan2007Member 2017-01-01 2017-06-30 0001435375 cik0001435375:AspenAdvanceOpportunityFundLPMember 2017-06-30 0001435375 cik0001435375:AspenAdvanceOpportunityFundLPMember 2016-12-31 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductOneMember 2017-01-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductTwoMember 2017-01-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductThreeMember 2017-01-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFourMember 2017-01-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFiveMember 2017-01-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductSixMember 2017-01-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductOneMember 2016-01-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductTwoMember 2016-01-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductThreeMember 2016-01-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFourMember 2016-01-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFiveMember 2016-01-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductSixMember 2016-01-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductOneMember 2017-04-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductOneMember 2016-04-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductTwoMember 2017-04-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductTwoMember 2016-04-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductThreeMember 2017-04-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductThreeMember 2016-04-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFourMember 2017-04-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFourMember 2016-04-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFiveMember 2017-04-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductFiveMember 2016-04-01 2016-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductSixMember 2017-04-01 2017-06-30 0001435375 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:ProductSixMember 2016-04-01 2016-06-30 0001435375 cik0001435375:GrantsAndLicensingRevenueConcentrationMember cik0001435375:GrantRevenueMember cik0001435375:GrantorOneMember 2017-01-01 2017-06-30 0001435375 cik0001435375:GrantsAndLicensingRevenueConcentrationMember cik0001435375:GrantRevenueMember cik0001435375:GrantorOneMember 2016-04-01 2016-06-30 0001435375 cik0001435375:GrantsAndLicensingRevenueConcentrationMember cik0001435375:GrantRevenueMember cik0001435375:GrantorOneMember 2016-01-01 2016-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerOneMember 2017-04-01 2017-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerTwoMember 2017-04-01 2017-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerMember 2016-04-01 2016-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember cik0001435375:CustomerMember 2017-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember cik0001435375:CustomerMember 2016-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2017-04-01 2017-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2016-04-01 2016-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember country:CN 2017-04-01 2017-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember currency:KRW 2016-04-01 2016-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember country:CN 2017-01-01 2017-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember currency:KRW 2017-01-01 2017-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember country:GB 2017-01-01 2017-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember currency:KRW 2016-01-01 2016-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerMember 2017-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerMember 2016-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerOneMember 2017-01-01 2017-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerTwoMember 2017-01-01 2017-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerOneMember 2016-01-01 2016-06-30 0001435375 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember cik0001435375:CustomerTwoMember 2016-01-01 2016-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2017-01-01 2017-06-30 0001435375 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2016-01-01 2016-06-30 0001435375 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-06-30 0001435375 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001435375 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001435375 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-01-01 2016-06-30 0001435375 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001435375 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:MichiganStateUniversityMember 2017-01-01 2017-06-30 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:MichiganStateUniversityMember 2016-01-01 2016-06-30 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:POSCOMember 2017-06-30 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:POSCOMember 2016-12-31 0001435375 cik0001435375:MasterLeasingAgreementMember cik0001435375:AspenAdvanceOpportunityFundLPMember us-gaap:SeriesAPreferredStockMember 2017-04-01 2017-06-30 0001435375 cik0001435375:MasterLeasingAgreementMember cik0001435375:AspenAdvanceOpportunityFundLPMember us-gaap:SeriesAPreferredStockMember 2016-04-01 2016-06-30 0001435375 cik0001435375:LicensingAgreementMember us-gaap:NotesPayableOtherPayablesMember cik0001435375:AAOFAndXGSIIMember 2013-03-18 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:AspenAdvanceOpportunityFundLPMember 2013-03-18 0001435375 us-gaap:ConvertiblePreferredStockMember 2017-06-30 0001435375 us-gaap:ConvertiblePreferredStockMember 2016-12-31 0001435375 us-gaap:SeriesBPreferredStockMember 2017-06-30 0001435375 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001435375 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001435375 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001435375 us-gaap:SeriesAPreferredStockMember 2017-06-30 0001435375 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-06-30 0001435375 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001435375 us-gaap:SeriesBPreferredStockMember 2017-06-30 0001435375 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001435375 us-gaap:CommonStockMember 2016-12-31 0001435375 us-gaap:CommonStockMember 2017-06-30 0001435375 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001435375 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001435375 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001435375 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001435375 us-gaap:RetainedEarningsMember 2016-12-31 0001435375 us-gaap:RetainedEarningsMember 2017-06-30 0001435375 2015-12-31 0001435375 2016-06-30 0001435375 us-gaap:SubsequentEventMember 2017-07-31 0001435375 us-gaap:SubsequentEventMember 2017-07-30 2017-07-31 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:MichiganStateUniversityMember 2017-04-01 2017-06-30 0001435375 cik0001435375:LicensingAgreementMember cik0001435375:MichiganStateUniversityMember 2016-04-01 2016-06-30 0001435375 cik0001435375:MasterLeasingAgreementMember cik0001435375:AspenAdvanceOpportunityFundLPMember us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001435375 cik0001435375:MasterLeasingAgreementMember cik0001435375:AspenAdvanceOpportunityFundLPMember us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure cik0001435375:Customer XG SCIENCES INC 0001435375 10-Q 2017-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2017 2100225 431107 1785343 1060224 959787 1000702 10000000 2000000 1000000 0.05 5000000 2000000 10000000 15000000 Additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016. Additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016. 14280 323578 266887 222262 539974 222262 833333 83333 56054 2635 1197617 58689 7140 7140 215050 14280 14280 1720400 2600000 1720400 2021-12-01 0.20 8.00 16.00 6.40 6.40 6.40 16.00 8.00 12.00 8.00 61000 50000 6000 5000 50000 Additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available if we have raised $10 million of equity capital after October 31, 2016. Secured by all of our assets. Payable beginning January 1, 2017 although we may elect to capitalize interest through January 1, 2019. One share of common stock for each $40 in loans received by us, equating to 20% warrant coverage, with an exercise price of $8.00 per share for the warrants issued at closing with the initial $2 million draw. 2023-12-01 5000000 56340 1918461 4270192 16.00 269987 224897 Common Series A PS Series A PS Series A PS Common 7798653 250300 6464160 646418 6554160 655418 437775 443790 246881 7900249 8.00 12.64 7.63 12.64 0.0143 0.0156 0.0127 0.0146 P4Y10M2D P5Y6M18D P6Y6M18D P7Y4M24D 0.3749 0.3769 0.3744 0.3792 101596 -3419 90000 9000 6015 178671 17862 12281 22541 1259 232614 -17500 103084 -1750 10308 -1559 7197 -32247 22259 -53056 142848 2009-07-01 2012-10-08 2016-12-14 2019-07-01 2027-10-08 2023-12-01 1200000 369750 0.20 Vesting of the options granted range from immediately to 20% per year, with most new options vesting on a straight-line basis over a four year period from the date issued. 8 P7Y 330000 295340 449368 34705 65595 260635 383773 200768 268667 200768 268667 59867 115106 59867 115106 0.24 0.15 0.12 0.11 0.12 0.16 0.39 0.11 0.15 0.14 0.10 0.94 1.00 1.00 0.34 0.24 0.30 0.50 0.72 0.25 0.40 0.15 0.16 0.14 0.37 0.15 0.11 0.17 0.15 0.60 0.74 2 1 2 2 37411 45964 155698 160009 193109 205973 7900249 7798653 8235163 7951132 -51417 -101596 -232614 100000 25000 175000 150000 10000000 1000000 131607 99078 165635 213789 174495 969612 2430524 2799346 2886421 195644 195499 551462 478019 4516064 5990463 750359 964757 7120 6428 958247 1239852 1918461 1862120 9776981 9877475 10735228 11117327 21805940 21634597 17134739 15647839 6666972 6490230 -51826815 -48899530 -6219164 -5126864 21634597 21805940 15647839 17134739 6490230 6666972 -48899530 -51826815 4516064 5990463 10000 10000 3000000 3000000 1500000 1500000 1843536 1829256 0 0 1843536 1829256 0 0 22122432 21951072 0 0 0 0 25000000 25000000 2100225 1885175 2100225 1885175 416779 141777 259079 82035 99489 158365 137055 50000 50000 25000 25000 566268 350142 284079 244090 210312 57052 93542 25020 786302 747947 415152 404232 996614 804999 508694 429252 -430346 -454857 -224615 -185162 490626 635357 227062 419007 1920352 1721603 923765 625381 2410978 2356960 1150827 1044388 -2841324 -2811817 -1375442 -1229550 113533 184774 54445 101123 101596 232614 -53056 142848 -74024 48000 -74000 24000 -85961 95840 -181501 65725 -2927285 -2715977 -1556943 -1163825 -2927285 1951406 862069 2054999 887595 -1.47 -3.15 -0.76 -1.31 1829256 1843536 1885175 2100225 233500 233500 171343 171343 14280 176742 176742 439078 456133 21180 17904 176742 228126 114295 157903 -101596 -232614 32529 -5930 -12864 -12624 -126196 79461 -213705 371606 -2384760 -1777826 352003 39314 94623 53647 -446626 -92961 9750 2832 750000 574750 1720400 2285032 233500 336600 1477150 1770350 -1354236 -100437 77646 171343 171343 NOTE 1 - NATURE OF BUSINESS AND BASIS OF PRESENTATION   XG Sciences, Inc., a Michigan company located in Lansing, Michigan and its subsidiary, XG Sciences IP, LLC (collectively referred to as “we”, “us”, “our”, or the “Company”) manufactures graphene nanoplatelets made from graphite, using two proprietary manufacturing processes to split natural flakes of crystalline graphite into very small and thin particles, which we sell as xGnP® graphene nanoplatelets. We sell our nanoparticles in the form of bulk powders or dispersions to other companies for use as additives to make composite and other materials with specially engineered characteristics. We also manufacture and sell integrated, value-added products containing these graphene nanoplatelets such as greases, composites, thin sheets, inks and coating formulations that we sell to other companies. Additionally, we license our technology to other companies in exchange for royalties and other fees.   Basis of Presentation   The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and do not include all of the information and footnotes required by GAAP for complete financial statements. All intercompany transactions have been eliminated in consolidation.   Certain information and footnote disclosures normally included in our annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these interim condensed consolidated financial statements. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016, as filed with the Securities and Exchange Commission (“SEC”) on Form 10-K on March 31, 2017.   The results of operations presented in this quarterly report are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Liquidity   We have historically incurred losses from operations and we may continue to generate negative cash flows as we implement our business plan. Our condensed consolidated financial statements are prepared using US GAAP as applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.   In December 2016, we entered into a draw loan note and agreement (the “Dow Facility”) with The Dow Chemical Company (“Dow”) to provide up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.    As of July 31, 2017, we had cash on hand of $1,000,702, and currently available funds of $2 million under the Dow Facility, which we believe will fund our operations for at least the next 12 months. We also have a commitment from a shareholder group, dated March 27, 2017, to provide up to $1 million of additional equity capital in the event we are unable to raise such funds from third party investors through the sale of our common stock in our initial public offering conducted pursuant to a Registration Statement on S-1 (Registration No. 333-209131) (the “IPO”). Our financial projections show that we may need to raise an additional $15 million or more before we are capable of achieving sustainable free cash flow after capital expenditures. We intend that the primary means for raising such funds will be through our IPO, the additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016. Thus far, we have raised $2.6 million through the sale of 323,578 shares of common stock between November 1, 2016 and June 30, 2017 towards the requirement to raise $10 million of additional equity capital in order to open up the remaining $5 million of availability on the Dow Facility. There can be no assurance that we will be able to raise additional equity capital in the IPO or in subsequent equity offerings or that the terms and conditions of any future financings will be workable or acceptable to us and our stockholders.    In the event we are unable to fund our operations from existing cash on hand, operating cash flows, additional borrowings or raising equity capital, we may be forced to reduce our expenses, slow down our growth rate, or discontinue operations. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.   Use of Estimates   The preparation of our condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, together with amounts disclosed in the related notes to the financial statements. Actual results and outcomes may differ from our estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these condensed consolidated financial statements include, but are not limited to, those related to revenue, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets, income taxes, the fair value of stock-based compensation and derivative financial instrument liabilities. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate.   Inventory   Inventory consists of raw materials, work-in-process and finished goods, all of which are valued at standard cost, which approximates average cost.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>The following amounts were included in inventory at the end of the period:</td> <td> </td> <td colspan="6" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">June 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; padding-left: 10pt; text-indent: -10pt">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">37,411</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">45,964</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">155,698</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,009</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">193,109</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">205,973</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Derivative Financial Instruments   We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. The terms of convertible preferred stock and convertible notes that we issue are reviewed to determine whether or not they contain embedded derivative instruments that are required by ASC 815: “Derivatives and Hedging” to be accounted for separately from the host contract, and recorded at fair value. In addition, freestanding warrants are also reviewed to determine if they achieve equity classification. Certain stock warrants that we have issued did not meet the conditions for equity classification and are classified as derivative instrument liabilities measured at fair value. The fair values of these derivative liabilities are revalued at each reporting date, with the change in fair value recognized in earnings. See Note 5 for additional information.   Fair Value Measurements   The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: justify"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: justify"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Balance at January 1</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">7,900,249</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">8,235,163</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants reclassified to equity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(51,417</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Gain recognized in earnings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(101,596</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(232,614</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Balance at June 30</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,798,653</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,951,132</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> NOTE 3 — FINANCING AGREEMENTS   Dow Facility   In December 2016, we entered into the Dow Facility which provides us with up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available if we have raised $10 million of equity capital after October 31, 2016.    The Dow Facility is senior to most of our other debt, and is secured by all of our assets (Dow is subordinate only to the capital leases with AAOF, see note 9). The loan does not mature until December 1, 2021 (subject to certain mandatory prepayments based on our equity financing activities). Interest is payable beginning January 1, 2017 although we may elect to capitalize interest through January 1, 2019. Dow received warrant coverage of one share of common stock for each $40 in loans received by us, equating to 20% warrant coverage, with an exercise price of $8.00 per share for the warrants issued at closing with the initial $2 million draw. After the initial closing, future warrants are subject to adjustment if we sell shares of common stock at a lower price. As of June 30, 2017, we had issued 50,000 warrants to Dow, which are exercisable on or before the expiration date of December 1, 2023.   The warrants meet the criteria for classification within stockholders’ equity. During the six months ended June 30, 2017, amortization expense of $56,340 was recognized resulting in a carrying value of $1,918,461 for the Dow Facility as of June 30, 2017.   The Dow Facility entitles Dow to appoint an observer to our board of directors (the “Board”). Dow will maintain their observation right until the later of December 1, 2019; or when the amount of principal and interest outstanding under the Dow Facility is less than $5 million. NOTE 4 — PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS   Private Placement   In April 2015, we commenced a private placement offering of Series B Units consisting of shares of Series B Preferred Stock and warrants to purchase common stock at an offering price of $16.00 per Series B Unit. During the period April 2015 through December 2016, we sold 266,887 shares of Series B Convertible Preferred Stock and Warrants to purchase 222,262 shares of common stock, for aggregate gross proceeds of $4,270,192.   The private placement Series B Unit offering was terminated on February 25, 2016. As a result of our IPO and pursuant to certain exchange rights granted to participants in the Series B Unit offering, holders of Series B Preferred Stock received the right to exchange each share of Series B Preferred Stock they owned into two shares of common stock. As of December 31, 2016, all holders of Series B Preferred Stock had exercised their Series B exchange rights, and as a result we issued 539,974 shares of restricted common stock in exchange for the 269,987 shares of Series B Preferred Stock that had been previously outstanding. All of the previously issued Series B Preferred Stock was cancelled. However, as of June 30, 2017, all of the 224,897 warrants issued in connection with the Series B Units remain outstanding. Such warrants have an exercise price of $16.00 per share and expire between April 21 and June 30, 2022. NOTE 5 – DERIVATIVE LIABILITY WARRANTS   The Series A Convertible Preferred Stock warrants issued in conjunction with convertible notes issued in 2013 (subsequently converted into Series A Preferred Stock), equipment financing leases procured in 2013 and 2014, and certain other pre-emptive rights and the common stock warrants issued in connection with the 2015 Series B Unit offering are derivative liabilities which require re-measurement at fair value each reporting period. Liability classification is required because the terms of the underlying Series A Convertible Preferred Stock have a conversion price reset in the event we offer shares below the then current price of our common stock, and the exchange rights issued in connection with the Series B Unit offering are not consistent with the definition for financial instruments indexed only to a company’s own stock.   The initial value of the stock warrants issued as consideration for the equipment financing leases in 2013 and 2014 was recorded as a reduction of the capital lease obligation and is being amortized as part of the effective interest cost on the capital lease obligation (see Note 8).   In 2014 when we entered into financing agreements with Samsung, AAOF and XGS II, we provided our shareholders with preemptive rights to purchase shares of Series A Convertible Preferred Stock for every two shares of Series A Convertible Preferred Stock or Common Stock owned by the shareholder. In addition, for every two shares of Series A Convertible Preferred Stock purchased by a shareholder, we issued such shareholder a warrant to purchase one additional share of Series A Convertible Preferred Stock with the same terms as the warrants issued to AAOF and XGS II.   Also, as part of our private placement in April 2015, shareholders and holders of our convertible notes were provided the right to purchase their pro rata share of any class of stock that the Company sells or issues. The sale of Series B Preferred Stock in the April 2015 offering triggered the preemptive rights resulting in the issuance of shares of Series B Preferred Stock and warrants.  As of June 30, 2017, the total number of Stock Warrants issued due to the preemptive rights offerings was 58,689.   Warrant shares indexed to derivative liabilities as of June 30, 2017 were as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Type of shares indexed</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Indexed Shares</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Warrants issued with Secured Convertible Notes</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Series A PS</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">6.40</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">833,333</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued with equipment financing leases</td> <td> </td> <td style="text-align: center">Series A PS</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.40</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">83,333</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants issued with Series A preemptive rights</td> <td> </td> <td style="text-align: center">Series A PS</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.40</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">56,054</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued with Series B preemptive rights</td> <td> </td> <td style="text-align: center">Common</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">16.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,635</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Warrants issued with Series B Units</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center">Common</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td> <td style="padding-bottom: 1pt; text-align: right">16.00</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">222,262</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total shares indexed to derivative liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,197,617</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The following table summarizes the fair value of the derivative liabilities as of June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31,2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Warrants issued with Secured Convertible Notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">6,464,160</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">6,554,160</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued with equipment financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">646,418</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">655,418</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants issued with preemptive rights</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">437,775</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">443,790</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Warrants issued with 2015 Series B Unit private placement</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">250,300</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">246,881</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Total derivative liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,798,653</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,900,249</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   We estimated the fair value of their warrant derivative liabilities as of June 30, 2017 and December 31, 2016, using a lattice model and the following assumptions:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: justify"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap" style="width: 72%; text-align: justify">Fair value of underlying stock</td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 11%; text-align: center">$8.00 - $12.64</td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 11%; text-align: center">$7.63 - $12.64</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td nowrap="nowrap" style="text-align: justify">Equivalent risk free interest rate</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">1.43% - 1.56%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">1.27%- 1.46%</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap" style="text-align: justify">Expected term (in years)</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">4.84 – 6.55</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">5.33- 7.04</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td nowrap="nowrap" style="text-align: justify">Equivalent stock price volatility</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">37.49% - 37.69%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">37.44%- 37.92%</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap" style="text-align: justify">Expected dividend yield</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">—</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">—</td> <td nowrap="nowrap"> </td></tr> </table>   The value of the warrants is estimated using a binomial lattice model. Equivalent amounts reflect the net results of multiple modeling simulations that the lattice model applies to underlying assumptions. Because we are not publicly traded on a national exchange or to our knowledge, an over-the-counter market, the expected volatility of our common stock was developed using historical volatility for a peer group for a period equal to the expected term of the warrants. The fair value of the warrants will be significantly influenced by the fair value of our common stock, stock price volatility, and the risk-free interest components of the lattice technique.   Changes in the fair value of Derivative Liabilities, carried at fair value, are reported as “Change in fair value of derivative liability — warrants” in the Statement of Operations, and were as follows:   <table cellspacing="0" cellpadding="0" style="width: 96%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Three Months Ended June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Six Months Ended June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2017</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2016</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2017</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with Secured Convertible Notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">(17,500</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">103,084</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">90,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">178,671</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with equipment financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,750</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,308</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17,862</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with preemptive rights</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,559</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,197</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,015</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,281</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with 2015 private placement</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,247</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">22,259</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,419</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">22,541</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with Bridge Financings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,259</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Total Derivative Gain (Loss)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">(53,056</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">142,848</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">101,596</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">232,614</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> NOTE 6 – STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS   The following table summarizes the warrants outstanding at June 30, 2017, which are accounted for as equity instruments, all of which are exercisable:   <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Date Issued</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of  Warrants</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="width: 57%">7/1/2009</td> <td style="width: 1%"> </td> <td style="width: 12%">7/1/2019</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">8.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">6,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">10/8/2012</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">10/8/2027</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">$</td> <td style="padding-bottom: 1pt; text-align: right">12.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">5,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="padding-bottom: 1pt">12/14/2016</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">12/1/2023</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">$</td> <td style="padding-bottom: 1pt; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: right">50,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td> </td> <td style="text-align: right">61,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> NOTE 7 – EQUITY INCENTIVE PLAN   We previously established the 2007 Stock Option Plan (the “2007 Plan”), which was scheduled to expire on October 30, 2017 and under which we granted key employees and directors options to purchase shares of our common stock at not less than fair market value as of the grant date. On May 4, 2017, the Board approved the 2017 Equity Incentive Plan (the “2017 Plan”) to replace the 2007 Stock Option Plan, which became effective upon the approval of the stockholders holding a majority of the voting power in the Company on July 18, 2017. The 2017 Plan replaces the 2007 Plan and authorizes us to issue awards (stock options and restricted stock) with respect of a maximum of 1,200,000 shares of our common stock, which equals the number of shares authorized under the 2007 Plan, as amended.      On July 24, 2017, certain stock options from the prior incentive stock option plan were cancelled and replacement stock options were awarded. The new stock option awards have an exercise price of $8 per share, a seven-year term, are vested to the same extent as the cancelled stock options, and are subject to certain other terms. The cancellation and reissuance of the stock options were treated as a modification under ASC 718, Compensation-Stock Compensation. The incremental value resulting from the modification, is estimated to be approximately $330,000, which will be recorded as compensation cost on the date of cancellation (for vested awards) or over the remaining requisite service period (for unvested awards).   The fair values of options granted are estimated on the dates of grant using the Black Scholes option-pricing model. As of June 30, 2017, 369,750 options to acquire shares have been granted cumulatively. Vesting of the options granted range from immediately to 20% per year, with most new options vesting on a straight-line basis over a four year period from the date issued. Rights to exercise the options that would have vested in any current service year vest immediately upon a change in control of the Company. The options expire at various dates through October 2023.    NOTE 8 – CAPITAL LEASES   As of June 30, 2017 and December 31, 2016, we have capital lease obligations as follows:   <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Capital lease obligations</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">295,340</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">449,368</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Unamortized warrant discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(34,705</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(65,595</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net obligations</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">260,635</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">383,773</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Short-term portion of obligations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(200,768</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(268,667</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Long-term portion of obligations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">59,867</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">115,106</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Our AAOF capital lease obligations are four year leases starting on January 1, 2014 and January 1, 2015. Our other capital leases expire at various dates in 2018, have average effective interest rates of 0% and contain bargain purchase options that allow us to purchase the leased property for a minimal amount upon the expiration of the lease term. NOTE 9 — Customer, Supplier, country, and Product Concentrations   Grants and Licensing Revenue Concentration   There was no grant revenue for the three months ended June 30, 2017. During the six months ended June 30, 2017, one grantor accounted for 94% of total grant revenue. During the three months ended June 30, 2016 and the six months ended June 30, 2016, one grantor accounted for 100% of the total grant revenue in each period. Our licensing revenue for the three months ended June 30, 2017 and 2016, and for the six months ended June 30, 2017 and 2016 came from one licensor.   Product Concentration   Concentrations of product sales greater than 10% of total product sales are shown in the table below. We attempt to minimize the risk associated with product concentrations by continuing to develop new products to add to our portfolio.     <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center">For the Three Months Ended June 30,</td> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center">For the Six Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="width: 38%"> </td> <td nowrap="nowrap" style="width: 14%; border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="width: 2%"> </td> <td nowrap="nowrap" style="width: 14%; border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="width: 2%"> </td> <td nowrap="nowrap" style="width: 14%; border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="width: 2%"> </td> <td nowrap="nowrap" style="width: 14%; border-bottom: black 1pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap">Grade C-300 HP</td> <td nowrap="nowrap" style="text-align: center">39%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">24%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap">Grade C-500</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">15%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap">Grade C-750</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">11%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">11%</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap">Grade R-10</td> <td nowrap="nowrap" style="text-align: center">15%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">14%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">12%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">12%</td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap">Grade M-15</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">16%</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap">Grade M-25</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">10%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td></tr> </table>   * Denotes less than 10% of product sales.   Customer Concentration   During the three months ended June 30, 2017 we had two customers whose purchases accounted for 34% and 24% of product sales. During the three months ended June 30, 2016 we had one customer who accounted for 30% of product sales.   For the six months ended June 30, 2017 we had two customers whose purchases accounted for 15%, and 11% of product sales. During the six months ended June 30, 2016 we had two customers whose purchases accounted for 17% and 15% of product sales.   At June 30, 2017, there were two customers who each had an accounts receivable balance greater than 10% of our total outstanding receivable balance. At June 30, 2016, there was only one customer who had an accounts receivable balance greater than 10% of our total outstanding receivable balance.   Country Concentration   We sell our products on a worldwide basis. All of these sales are denominated in U.S. dollars.   International sales for the three months ended June 30, 2017 were 50% of product sales as compared with 72% for the three months ended June 30, 2016. One country, China, accounted for 25% of product sales for the three months ended June 30, 2017 and one country, South Korea, accounted for 40% of product sales for the three months ended June 30, 2016.   International sales for the six months ended June 30, 2017 were 60% of product sales as compared with 74% for the six months ended June 30, 2016. Three countries, China, South Korea, and the United Kingdom accounted for approximately 15%, 16%, and 14%, respectively, of product sales for the six months ended June 30, 2017 and one country, South Korea, accounted for 37% of product sales for the six months ended June 30, 2016.   Suppliers   We buy raw materials used in manufacturing from several sources. These materials are available from a large number of sources. Thus, we believe a change in suppliers would have no material effect on our operations. We did not have any purchases from one supplier that were more than 10% of total purchases for the three months and six months ended June 30, 2017 and 2016. NOTE 10 - RELATED PARTY TRANSACTIONS   We have a licensing agreement for exclusive use of patents and pending patents with Michigan State University (“MSU”), a shareholder of the Company via the MSU Foundation. During the three months ended June 30, 2017 and 2016 we recorded licensing expense of $12,500 per quarter. During the six months ended June 30, 2017 and 2016 we recorded licensing expense of $25,000 in each period.   We have also entered into product licensing agreements with, POSCO, a shareholder. See below for POSCO. Other than MSU and POSCO, there were no other royalty expenses or revenue recognized during the three or six months ended June 30, 2017 and 2016.   Beginning in 2014, POSCO, a licensee and shareholder of the Company, has had a contractual obligation to pay a minimum royalty of $100,000 per year to license certain technologies. This obligation is due annually on February 28 of the following year. We record this license revenue at a rate of $25,000 per quarter. POSCO is disputing its obligation to pay the minimum royalty and has not paid the royalty in any prior year. We filed a demand for arbitration in the International Court of Arbitration (ICA) on March 9, 2016 in an effort to resolve the dispute. The ICA has assigned an arbitrator, but no decision has been reached in the dispute. Allowances in the amounts of $175,000 and $150,000 were recorded at June 30, 2017 and December 31, 2016, respectively, to reflect an estimate of the portion of the 2017, 2016, 2015 and 2014 royalties that we believe may not be collectible. The accrued royalty and allowance are netted together and reflected in other current assets on the condensed consolidated balance sheet.    On March 18, 2013, we entered into a series of agreements with two private investment funds: Aspen Advanced Opportunity Fund, LP (“AAOF”) and XGS II, LLC (“XGS II”), and pursuant to a Shareholders’ Agreement dated March 18, 2013 (as amended on February 26, 2016), a principal of each private fund serves as a member of our Board of Directors. These financing agreements were amended and restated on July 12, 2013 to provide for expanded financing commitments from AAOF and XGS II. Pursuant to these agreements, AAOF and XGS II agreed to provide $10 million of financing to the Company in the form of Secured Convertible Notes and AAOF agreed to provide an additional $1.0 million of lease financing arrangements. All of the principal and accrued interest on the Secured Convertible Notes issued to AAOF and XGS II were converted into Series A Preferred Stock in December 2016.   During the three months ended June 30, 2017 and 2016 we issued 7,140 shares per period of Series A Preferred stock to AAOF as payment for lease financing obligations under the terms of the Master Lease Agreement, dated March 18, 2013. For the six months ended June 30, 2017 and 2016 we issued a total of 14,280 shares per period as payment for lease obligations. Liquidity   We have historically incurred losses from operations and we may continue to generate negative cash flows as we implement our business plan. Our condensed consolidated financial statements are prepared using US GAAP as applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.   In December 2016, we entered into a draw loan note and agreement (the “Dow Facility”) with The Dow Chemical Company (“Dow”) to provide up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.    As of July 31, 2017, we had cash on hand of $1,000,702, and currently available funds of $2 million under the Dow Facility, which we believe will fund our operations for at least the next 12 months. We also have a commitment from a shareholder group, dated March 27, 2017, to provide up to $1 million of additional equity capital in the event we are unable to raise such funds from third party investors through the sale of our common stock in our initial public offering conducted pursuant to a Registration Statement on S-1 (Registration No. 333-209131) (the “IPO”). Our financial projections show that we may need to raise an additional $15 million or more before we are capable of achieving sustainable free cash flow after capital expenditures. We intend that the primary means for raising such funds will be through our IPO, the additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016. Thus far, we have raised $2.6 million through the sale of 323,578 shares of common stock between November 1, 2016 and June 30, 2017 towards the requirement to raise $10 million of additional equity capital in order to open up the remaining $5 million of availability on the Dow Facility. There can be no assurance that we will be able to raise additional equity capital in the IPO or in subsequent equity offerings or that the terms and conditions of any future financings will be workable or acceptable to us and our stockholders.   In the event we are unable to fund our operations from existing cash on hand, operating cash flows, additional borrowings or raising equity capital, we may be forced to reduce our expenses, slow down our growth rate, or discontinue operations. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.   Use of Estimates   The preparation of our condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, together with amounts disclosed in the related notes to the financial statements. Actual results and outcomes may differ from our estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these condensed consolidated financial statements include, but are not limited to, those related to revenue, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets, income taxes, the fair value of stock-based compensation and derivative financial instrument liabilities. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate. Inventory   Inventory consists of raw materials, work-in-process and finished goods, all of which are valued at standard cost, which approximates average cost.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>The following amounts were included in inventory at the end of the period:</td> <td> </td> <td colspan="6" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">June 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; padding-left: 10pt; text-indent: -10pt">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">37,411</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">45,964</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">155,698</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,009</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">193,109</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">205,973</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Derivative Financial Instruments   We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. The terms of convertible preferred stock and convertible notes that we issue are reviewed to determine whether or not they contain embedded derivative instruments that are required by ASC 815: “Derivatives and Hedging” to be accounted for separately from the host contract, and recorded at fair value. In addition, freestanding warrants are also reviewed to determine if they achieve equity classification. Certain stock warrants that we have issued did not meet the conditions for equity classification and are classified as derivative instrument liabilities measured at fair value. The fair values of these derivative liabilities are revalued at each reporting date, with the change in fair value recognized in earnings. See Note 5 for additional information. Fair Value Measurements   The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: justify"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: justify"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Balance at January 1</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">7,900,249</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">8,235,163</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants reclassified to equity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(51,417</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Gain recognized in earnings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(101,596</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(232,614</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Balance at June 30</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,798,653</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,951,132</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>The following amounts were included in inventory at the end of the period:</td> <td> </td> <td colspan="6" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">June 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; padding-left: 10pt; text-indent: -10pt">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">37,411</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">45,964</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">155,698</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,009</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">193,109</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">205,973</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: justify"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: justify"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Balance at January 1</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">7,900,249</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">8,235,163</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants reclassified to equity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(51,417</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Gain recognized in earnings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(101,596</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(232,614</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Balance at June 30</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,798,653</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,951,132</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrant shares indexed to derivative liabilities as of June 30, 2017 were as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Type of shares indexed</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Indexed Shares</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Warrants issued with Secured Convertible Notes</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Series A PS</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">6.40</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">833,333</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued with equipment financing leases</td> <td> </td> <td style="text-align: center">Series A PS</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.40</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">83,333</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants issued with Series A preemptive rights</td> <td> </td> <td style="text-align: center">Series A PS</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">6.40</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">56,054</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued with Series B preemptive rights</td> <td> </td> <td style="text-align: center">Common</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">16.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,635</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Warrants issued with Series B Units</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center">Common</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td> <td style="padding-bottom: 1pt; text-align: right">16.00</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">222,262</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total shares indexed to derivative liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,197,617</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the fair value of the derivative liabilities as of June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31,2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Warrants issued with Secured Convertible Notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">6,464,160</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">6,554,160</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued with equipment financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">646,418</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">655,418</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants issued with preemptive rights</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">437,775</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">443,790</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Warrants issued with 2015 Series B Unit private placement</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">250,300</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">246,881</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Total derivative liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,798,653</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,900,249</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> We estimated the fair value of their warrant derivative liabilities as of June 30, 2017 and December 31, 2016, using a lattice model and the following assumptions:   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: justify"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap" style="width: 72%; text-align: justify">Fair value of underlying stock</td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 11%; text-align: center">$8.00 - $12.64</td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 1%"> </td> <td nowrap="nowrap" style="width: 11%; text-align: center">$7.63 - $12.64</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td nowrap="nowrap" style="text-align: justify">Equivalent risk free interest rate</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">1.43% - 1.56%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">1.27%- 1.46%</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap" style="text-align: justify">Expected term (in years)</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">4.84 – 6.55</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">5.33- 7.04</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td nowrap="nowrap" style="text-align: justify">Equivalent stock price volatility</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">37.49% - 37.69%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">37.44%- 37.92%</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td nowrap="nowrap" style="text-align: justify">Expected dividend yield</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">—</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">—</td></tr> </table> Changes in the fair value of Derivative Liabilities, carried at fair value, are reported as “Change in fair value of derivative liability — warrants” in the Statement of Operations, and were as follows:   <table cellspacing="0" cellpadding="0" style="width: 96%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Three Months Ended June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Six Months Ended June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2017</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2016</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2017</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with Secured Convertible Notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">(17,500</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">103,084</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">90,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">178,671</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with equipment financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,750</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,308</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17,862</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with preemptive rights</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,559</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,197</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,015</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,281</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with 2015 private placement</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(32,247</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">22,259</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,419</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">22,541</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Warrants issued with Bridge Financings</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,259</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 17.15pt; text-indent: -17.15pt">Total Derivative Gain (Loss)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">(53,056</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">142,848</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">101,596</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">232,614</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The following table summarizes the warrants outstanding at June 30, 2017, which are accounted for as equity instruments, all of which are exercisable:   <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Date Issued</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of  Warrants</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="width: 57%">7/1/2009</td> <td style="width: 1%"> </td> <td style="width: 12%">7/1/2019</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">8.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">6,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">10/8/2012</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">10/8/2027</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">$</td> <td style="padding-bottom: 1pt; text-align: right">12.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">5,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #cceeff"> <td style="padding-bottom: 1pt">12/14/2016</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">12/1/2023</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">$</td> <td style="padding-bottom: 1pt; text-align: right">8.00</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: right">50,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td> </td> <td style="text-align: right">61,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> As of June 30, 2017 and December 31, 2016, we have capital lease obligations as follows:   <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">Capital lease obligations</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">295,340</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">449,368</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Unamortized warrant discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(34,705</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(65,595</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net obligations</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">260,635</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">383,773</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Short-term portion of obligations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(200,768</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(268,667</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Long-term portion of obligations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">59,867</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">115,106</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25000 25000 12500 12500 Concentrations of product sales greater than 10% of total product sales are shown in the table below. We attempt to minimize the risk associated with product concentrations by continuing to develop new products to add to our portfolio.   <table cellspacing="0" cellpadding="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center">For the Three Months Ended June 30,</td> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center">For the Six Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="width: 32%"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; width: 20%">2017</td> <td nowrap="nowrap" style="width: 2%"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; width: 14%">2016</td> <td nowrap="nowrap" style="width: 2%"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; width: 14%">2017</td> <td nowrap="nowrap" style="width: 2%"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; width: 14%">2016</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td nowrap="nowrap">Grade C-300 HP</td> <td nowrap="nowrap" style="text-align: center">39%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">24%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap">Grade C-500</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">15%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td nowrap="nowrap">Grade C-750</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">11%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">11%</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap">Grade R-10</td> <td nowrap="nowrap" style="text-align: center">15%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">14%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">12%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">12%</td></tr> <tr style="background-color: #cceeff; vertical-align: bottom"> <td nowrap="nowrap">Grade M-15</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">16%</td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap">Grade M-25</td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">10%</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="text-align: center">*</td></tr> </table>   * Denotes less than 10% of product sales. Denotes less than 10% of product sales. EX-101.SCH 11 cik0001435375-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIT) (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - FINANCING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - DERIVATIVE LIABILITY WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - EQUITY INCENTIVE PLAN link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - CAPITAL LEASES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CAPITAL LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - FINANCING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - EQUITY INCENTIVE PLAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - CAPITAL LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 cik0001435375-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 cik0001435375-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 14 cik0001435375-20170630_lab.xml XBRL LABEL FILE Legal Entity [Axis] The Dow Chemical Company [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Draw Loan Note And Agreement [Member] Debt Instrument [Axis] Senior Secured Debt Financing [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Equity Components [Axis] Warrant [Member] Sale of Stock [Axis] Private Placement [Member] Class of Warrant or Right [Axis] Warrant [Member] Class of Stock [Axis] Series B Preferred stock [Member] Restricted Common Stock [Member] Secured Convertible Notes [Member] Equipment Financing Leases [Member] Financing Agreements With Samsung, Ventures And Aspen Advanced Opportunity Fund LP, AAOF and XGS II [Member] Preemptive Rights Offering [Member] Series A Convertible Preferred Stock [Member] Related Party [Axis] Existing Stockholders [Member] Range [Axis] Minimum [Member] Maximum [Member] Bridge Financings [Member] 15 Investors [Member] Warrant 1 [Member] Warrant 2 [Member] Plan Name [Axis] Incentive Stock Option Plan [Member] 2007 Stock Option Plan [Member] Aspen Advance Opportunity Fund, LP [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Concentration Risk Benchmark [Axis] Total Product Revenues [Member] Products and Services [Axis] Grade C-300 HP [Member] Grade C-500 [Member] Grade C-750 [Member] Grade R-10 [Member] Grade M-15 [Member] Grade M-25 [Member] Grants and Licensing Revenue Concentration [Member] Total Grant Revenue [Member] Grantor One [Member] Customer Concentration Risk [Member] Customer [Axis] Customer One [Member] Customer Two [Member] Customer [Member] Accounts Receivable Greater Than 10% [Member] Country Concentration Risk [Member] Geographic Distribution [Axis] Foreign [Member] Geographical [Axis] China Korea (South) United Kingdom Fair Value, Hierarchy [Axis] Significant Unobservable Inputs (Level 3) [Member] Measurement Frequency [Axis] Recurring [Member] Licensing Agreement [Member] Michigan State University (Patents and Pending Patents) [Member] POSCO [Member] Master Leasing Agreement [Member] Aspen Advance Opportunity Fund, LP (AAOF) [Member] Series A Preferred stock [Member] Aspen Advanced Opportunity Fund, LP ("AAOF") and XGS II, LLC ("XGS II") [Member] Common stock [Member] Additional paid-in capital [Member] Accumulated deficit [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Accounts receivable, less allowance for doubtful accounts of $10,000 at June 30, 2017 and December 31, 2016 Inventory Incentive refunds receivable Other current assets Total current assets PROPERTY, PLANT AND EQUIPMENT, NET RESTRICTED CASH FOR LETTER OF CREDIT INTANGIBLE ASSETS, NET TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable and other liabilities Deferred revenue Current portion of capital lease obligations Total current liabilities LONG TERM LIABILITIES Long term portion of capital lease obligations Long term debt Derivative liability - warrants Total long term liabilities TOTAL LIABILITIES STOCKHOLDERS' DEFICIT Preferred stock, value Common stock, no par value, 25,000,000 shares authorized, 2,100,225 and 1,885,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively Additional paid in capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Allowance for doubtful accounts Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Preferred stock, liquidation value Common stock, no par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Condensed Consolidated Statements Of Operations REVENUE Product sales Grants Licensing revenue Total revenue COST OF GOODS SOLD Direct costs Unallocated manufacturing expenses Total cost of goods sold GROSS LOSS OPERATING EXPENSES Research and development Sales, general and administrative Total operating expenses OPERATING LOSS OTHER INCOME (EXPENSE) Interest expense, net Gain (Loss) from change in fair value of derivative liability - warrants Government incentives, net Total other income (expense) NET LOSS WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic and diluted (in shares) NET LOSS PER SHARE - Basic and diluted (in dollars per share) Increase (Decrease) in Stockholders' Equity [Roll Forward] Balances at beginning Balances at beginning (in shares) Stock issued for cash Stock issued for cash (in shares) Stock issuance fees and expenses Preferred stock issued to pay capital lease obligations Preferred stock issued to pay capital lease obligations (in shares) Employee stock option expense Net loss Balances at ending Balances at ending (in shares) Condensed Consolidated Statements Of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Amortization of intangible assets Stock-based compensation expense Non-cash interest expense Gain from change in fair value of derivative liability - warrants (Increase) Decrease in: Accounts receivable Inventory Other current and non-current assets Increase (Decrease) in: Accounts payable and other liabilities NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment Purchases of intangible assets NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Repayments of capital lease obligations Repayments of short-term notes Advances on short-term notes Proceeds from issuance of common stock Common stock issuance fees and expenses NET CASH PROVIDED BY FINANCING ACTIVITIES NET DECREASE IN CASH CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING: Value of preferred stock issued for AAOF capital lease obligations Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF BUSINESS AND BASIS OF PRESENTATION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Debt Disclosure [Abstract] FINANCING AGREEMENTS Warrants and Rights Note Disclosure [Abstract] PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE LIABILITY WARRANTS Equity [Abstract] STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS Disclosure of Compensation Related Costs, Share-based Payments [Abstract] EQUITY INCENTIVE PLAN Capital Leases of Lessee [Abstract] CAPITAL LEASES Risks and Uncertainties [Abstract] CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Liquidity Use of Estimates Inventory Derivative Financial Instruments Fair Value Measurements Schedule of inventory Schedule of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) Schedule of shares indexed to derivative liabilities Schedule of fair value of derivative liabilities Schedule of warrant derivative liabilities Schedule of changes in fair value of derivative liability - warrants Stock Warrants Tables Schedule of warrants outstanding Schedule of capital lease obligations Customer Supplier Country And Product Concentrations Tables Concentrations of product sales Raw materials Finished goods Total Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Balance at beginning Warrants reclassified to equity Gain recognized in earnings Balance at ending Cash in hand Face amount Proceeds from secured debt Interest rate Proceeds from issuance of initial public offering Revenues Funds available from operations Additional fund required for next 12 months Additional fund required for sustainable cash flow Description of raising fund Number of common shares sold Value of common shares sold Short-term loan Maturity date Percentage of common stock warrant coverage Exercise price (in dollars per share) Number of common stock warrants issued Description of funding Description of collateral Description of interest payable terms Description of warrant coverage Warrant expiration date Amount of principal and interest outstanding Amortization expense Secured debt carrying amount Proceeds from private placement Number of shares issued Share price (in dollars per unit) Number of shares converted Number of warrants outstanding Exercise Price Type of shares indexed Total derivative liabilities Fair value of underlying stock Equivalent risk free interest rate Expected term (in years) Equivalent stock price volatility Expected dividend yield Total Derivative Gain Date Issued Expiration Date Number of Warrants Maximum number of options authorized Number of option granted Vesting percent, per year Description of vesting terms Options expiration year Exercise price (in dollars per share) Vesting period Compensation cost Capital lease obligations Unamortized warrant discount Net obligations Short-term portion of obligations Long-term portion of obligations Concentration of risk Number of customers Description of product Licensing expenses Minimum yearly contractual obligation Quarterly license revenue Allowance contractual obligation Lease financing Information about legal entity. Information about agreement. Funds available from operations. Additional fund required for next 12 months. Additional fund required for sustainable cash flow. Description of raising fund. Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Information related to percentage of common stock warrant coverage. Information related to number of warrants issued during period. Explanation of funding. Explanation of warrant. Date which warrant is set to expire, in CCYY-MM-DD format. Amount of principal and interest outstanding. Per unit amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. Information by category of arrangement, Information by type of preemptive rights offering. Information by type of related party. The entire disclosure for type of shares indexed. Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Date the warrants or rights are exercisable, in CCYY-MM-DD format. Date the warrants or rights are exercisable, in CCYY-MM-DD format. Information by plan name pertaining to equity-based compensation arrangements. Information by plan name pertaining to equity-based compensation arrangements. Date the equity-based award expires, in CCYY-MM-DD format. Information about legal entity. Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date. Information related to unamortized warrant discount. Information about product. Information about product. Information about product. Information about product. Information about product. Information about product. Information about grant and licensin revenue concentration. Information about grant revenue. Information about legal entity. Information about customer. Information about customer. Information about customer. Represents the number of customers. Information by category of arrangement, Information by type of related party. Information by type of related party. Information by category of arrangement, The set of legal entities associated with a report. Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. Amount of lease financing. Amount of incentive refunds receivable. Amount of restricted cash for letter of credit. The gross result for the period of deducting operating expenses from operating revenues. Amount of incentive refund and interest income. Represent information about the stock issued during period value for the shares preferred stock issued to pay capital lease obligations. Represent information about the stock issued during period shares preferred stock issued to pay capital lease obligations. The amount gain from change in derivative liability warrants. Equity impact of the value of preferred stock issued for capita; lease obligations. The entire disclosure of liquidity. Tabular disclosure of shares indexed to derivative liabilities. Tabular disclosure of change in fair value of derivative liability warrants. Warrant [Member] [Default Label] Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Revenue, Net Cost of Goods and Services Sold OperatingGrossLoss Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Shares, Outstanding Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Investing Activities, Continuing Operations Repayments of Debt and Capital Lease Obligations Repayments of Short-term Debt Payments of Stock Issuance Costs Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash, Period Increase (Decrease) Inventory, Policy [Policy Text Block] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price UnamortizedWarrantDiscount Capital Lease Obligations EX-101.PRE 15 cik0001435375-20170630_pre.xml XBRL PRESENTATION FILE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2017

Aug. 11, 2017

Document And Entity Information

Entity Registrant Name XG SCIENCES INC

Entity Central Index Key 0001435375

Document Type 10-Q

Document Period End Date Jun. 30, 2017

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity a Well-known Seasoned Issuer No

Entity a Voluntary Filer No

Entity's Reporting Status Current Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 2,100,225

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2017

X

- References
No definition available.
+ Details

Name: cik0001435375_DocumentAndEntityInformationAbstract

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)

Jun. 30, 2017

Dec. 31, 2016

CURRENT ASSETS

Cash $ 431,107 $ 1,785,343

Accounts receivable, less allowance for doubtful accounts of $10,000 at June 30, 2017 and December 31, 2016 131,607 99,078

Inventory 193,109 205,973

Incentive refunds receivable 165,635

Other current assets 213,789 174,495

Total current assets 969,612 2,430,524

PROPERTY, PLANT AND EQUIPMENT, NET 2,799,346 2,886,421

RESTRICTED CASH FOR LETTER OF CREDIT 195,644 195,499

INTANGIBLE ASSETS, NET 551,462 478,019

TOTAL ASSETS 4,516,064 5,990,463

CURRENT LIABILITIES

Accounts payable and other liabilities 750,359 964,757

Deferred revenue 7,120 6,428

Current portion of capital lease obligations 200,768 268,667

Total current liabilities 958,247 1,239,852

LONG TERM LIABILITIES

Long term portion of capital lease obligations 59,867 115,106

Long term debt 1,918,461 1,862,120

Derivative liability - warrants 7,798,653 7,900,249

Total long term liabilities 9,776,981 9,877,475

TOTAL LIABILITIES 10,735,228 11,117,327

STOCKHOLDERS' DEFICIT

Common stock, no par value, 25,000,000 shares authorized, 2,100,225 and 1,885,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively 17,134,739 15,647,839

Additional paid in capital 6,666,972 6,490,230

Accumulated deficit (51,826,815) (48,899,530)

Total stockholders' deficit (6,219,164) (5,126,864)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT 4,516,064 5,990,463

Series A Convertible Preferred Stock [Member]

STOCKHOLDERS' DEFICIT

Preferred stock, value 21,805,940 21,634,597

Series B Preferred stock [Member]

STOCKHOLDERS' DEFICIT

Preferred stock, value

X

- Definition
Amount of incentive refunds receivable.
+ References
No definition available.
+ Details

Name: cik0001435375_IncentiveRefundsReceivable

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of restricted cash for letter of credit.
+ References
No definition available.
+ Details

Name: cik0001435375_RestrictedCashForLetterOfCredit

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735
+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13495-108611
+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)

Jun. 30, 2017

Dec. 31, 2016

Allowance for doubtful accounts $ 10,000 $ 10,000

Common stock, no par value (in dollars per share) $ 0 $ 0

Common stock, authorized 25,000,000 25,000,000

Common stock, issued 2,100,225 1,885,175

Common stock, outstanding 2,100,225 1,885,175

Series A Convertible Preferred Stock [Member]

Preferred stock, authorized 3,000,000 3,000,000

Preferred stock, issued 1,843,536 1,829,256

Preferred stock, outstanding 1,843,536 1,829,256

Preferred stock, liquidation value $ 22,122,432 $ 21,951,072

Series B Preferred stock [Member]

Preferred stock, authorized 1,500,000 1,500,000

Preferred stock, issued 0 0

Preferred stock, outstanding 0 0

Preferred stock, liquidation value $ 0 $ 0

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of the difference between preference in liquidation and the par or stated values of the preferred shares.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

REVENUE

Product sales $ 259,079 $ 82,035 $ 416,779 $ 141,777

Grants 137,055 99,489 158,365

Licensing revenue 25,000 25,000 50,000 50,000

Total revenue 284,079 244,090 566,268 350,142

COST OF GOODS SOLD

Direct costs 93,542 25,020 210,312 57,052

Unallocated manufacturing expenses 415,152 404,232 786,302 747,947

Total cost of goods sold 508,694 429,252 996,614 804,999

GROSS LOSS (224,615) (185,162) (430,346) (454,857)

OPERATING EXPENSES

Research and development 227,062 419,007 490,626 635,357

Sales, general and administrative 923,765 625,381 1,920,352 1,721,603

Total operating expenses 1,150,827 1,044,388 2,410,978 2,356,960

OPERATING LOSS (1,375,442) (1,229,550) (2,841,324) (2,811,817)

OTHER INCOME (EXPENSE)

Interest expense, net (54,445) (101,123) (113,533) (184,774)

Gain (Loss) from change in fair value of derivative liability - warrants (53,056) 142,848 101,596 232,614

Government incentives, net (74,000) 24,000 (74,024) 48,000

Total other income (expense) (181,501) 65,725 (85,961) 95,840

NET LOSS $ (1,556,943) $ (1,163,825) $ (2,927,285) $ (2,715,977)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic and diluted (in shares) 2,054,999 887,595 1,951,406 862,069

NET LOSS PER SHARE - Basic and diluted (in dollars per share) $ (0.76) $ (1.31) $ (1.47) $ (3.15)

X

- Definition
Amount of incentive refund and interest income.
+ References
No definition available.
+ Details

Name: cik0001435375_IncentiveRefundAndInterestIncome

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gross result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: cik0001435375_OperatingGrossLoss

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cost of materials used in goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSoldDirectMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84234895&loc=SL5618551-113959
+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred in the production of goods for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_ManufacturingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SalesRevenueNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIT) (unaudited) - 6 months ended Jun. 30, 2017 - USD ($)

Series A Preferred stock [Member]

Series B Preferred stock [Member]

Common stock [Member]

Additional paid-in capital [Member]

Accumulated deficit [Member]

Total

Balances at beginning at Dec. 31, 2016 $ 21,634,597 $ 15,647,839 $ 6,490,230 $ (48,899,530) $ (5,126,864)

Balances at beginning (in shares) at Dec. 31, 2016 1,829,256 1,885,175

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Stock issued for cash $ 1,720,400 $ 1,720,400

Stock issued for cash (in shares) 215,050 14,280

Stock issuance fees and expenses $ (233,500) $ (233,500)

Preferred stock issued to pay capital lease obligations $ 171,343 171,343

Preferred stock issued to pay capital lease obligations (in shares) 14,280

Employee stock option expense 176,742 176,742

Net loss (2,927,285) (2,927,285)

Balances at ending at Jun. 30, 2017 $ 21,805,940 $ 17,134,739 $ 6,666,972 $ (51,826,815) $ (6,219,164)

Balances at ending (in shares) at Jun. 30, 2017 1,843,536 2,100,225

X

- Definition
Represent information about the stock issued during period shares preferred stock issued to pay capital lease obligations.
+ References
No definition available.
+ Details

Name: cik0001435375_StockIssuedDuringPeriodSharesPreferredAStockIssuedToPayCapitalLeaseObligations

Namespace Prefix: cik0001435375_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represent information about the stock issued during period value for the shares preferred stock issued to pay capital lease obligations.
+ References
No definition available.
+ Details

Name: cik0001435375_StockIssuedDuringPeriodValuePreferredAStockIssuedToPayCapitalLeaseObligations

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid-in capital (APIC) from recognition of equity-based compensation for employee stock purchase program.
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss $ (2,927,285) $ (2,715,977)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 439,078 456,133

Amortization of intangible assets 21,180 17,904

Stock-based compensation expense 176,742 228,126

Non-cash interest expense 114,295 157,903

Gain from change in fair value of derivative liability - warrants (101,596) (232,614)

(Increase) Decrease in:

Accounts receivable (32,529) 5,930

Inventory 12,864 12,624

Other current and non-current assets 126,196 (79,461)

Increase (Decrease) in:

Accounts payable and other liabilities (213,705) 371,606

NET CASH USED IN OPERATING ACTIVITIES (2,384,760) (1,777,826)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property and equipment (352,003) (39,314)

Purchases of intangible assets (94,623) (53,647)

NET CASH USED IN INVESTING ACTIVITIES (446,626) (92,961)

CASH FLOWS FROM FINANCING ACTIVITIES

Repayments of capital lease obligations (9,750) (2,832)

Repayments of short-term notes (750,000)

Advances on short-term notes 574,750

Proceeds from issuance of common stock 1,720,400 2,285,032

Common stock issuance fees and expenses (233,500) (336,600)

NET CASH PROVIDED BY FINANCING ACTIVITIES 1,477,150 1,770,350

NET DECREASE IN CASH (1,354,236) (100,437)

CASH AT BEGINNING OF PERIOD 1,785,343 1,060,224

CASH AT END OF PERIOD 431,107 959,787

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Cash paid for interest 77,646

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING:

Value of preferred stock issued for AAOF capital lease obligations $ 171,343 $ 171,343

X

- Definition
The amount gain from change in derivative liability warrants.
+ References
No definition available.
+ Details

Name: cik0001435375_GainFromChangeInFairValueOfDerivativeLiabilityWarrants

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Equity impact of the value of preferred stock issued for capita; lease obligations.
+ References
No definition available.
+ Details

Name: cik0001435375_ValueOfPreferredStockIssuedForCapitalLeaseObligations

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense or loss included in net income that result in no cash flow, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1

NATURE OF BUSINESS AND BASIS OF PRESENTATION
6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF BUSINESS AND BASIS OF PRESENTATION
NOTE 1 - NATURE OF BUSINESS AND BASIS OF PRESENTATION

XG Sciences, Inc., a Michigan company located in Lansing, Michigan and its subsidiary, XG Sciences IP, LLC (collectively referred to as “we”, “us”, “our”, or the “Company”) manufactures graphene nanoplatelets made from graphite, using two proprietary manufacturing processes to split natural flakes of crystalline graphite into very small and thin particles, which we sell as xGnP^® graphene nanoplatelets. We sell our nanoparticles in the form of bulk powders or dispersions to other companies for use as additives to make composite and other materials with specially engineered characteristics. We also manufacture and sell integrated, value-added products containing these graphene nanoplatelets such as greases, composites, thin sheets, inks and coating formulations that we sell to other companies. Additionally, we license our technology to other companies in exchange for royalties and other fees.

Basis of Presentation

The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and do not include all of the information and footnotes required by GAAP for complete financial statements. All intercompany transactions have been eliminated in consolidation.

Certain information and footnote disclosures normally included in our annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these interim condensed consolidated financial statements. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016, as filed with the Securities and Exchange Commission (“SEC”) on Form 10-K on March 31, 2017.

The results of operations presented in this quarterly report are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Liquidity

We have historically incurred losses from operations and we may continue to generate negative cash flows as we implement our business plan. Our condensed consolidated financial statements are prepared using US GAAP as applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

In December 2016, we entered into a draw loan note and agreement (the “Dow Facility”) with The Dow Chemical Company (“Dow”) to provide up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.

As of July 31, 2017, we had cash on hand of $1,000,702, and currently available funds of $2 million under the Dow Facility, which we believe will fund our operations for at least the next 12 months. We also have a commitment from a shareholder group, dated March 27, 2017, to provide up to $1 million of additional equity capital in the event we are unable to raise such funds from third party investors through the sale of our common stock in our initial public offering conducted pursuant to a Registration Statement on S-1 (Registration No. 333-209131) (the “IPO”). Our financial projections show that we may need to raise an additional $15 million or more before we are capable of achieving sustainable free cash flow after capital expenditures. We intend that the primary means for raising such funds will be through our IPO, the additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016. Thus far, we have raised $2.6 million through the sale of 323,578 shares of common stock between November 1, 2016 and June 30, 2017 towards the requirement to raise $10 million of additional equity capital in order to open up the remaining $5 million of availability on the Dow Facility. There can be no assurance that we will be able to raise additional equity capital in the IPO or in subsequent equity offerings or that the terms and conditions of any future financings will be workable or acceptable to us and our stockholders.



In the event we are unable to fund our operations from existing cash on hand, operating cash flows, additional borrowings or raising equity capital, we may be forced to reduce our expenses, slow down our growth rate, or discontinue operations. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Use of Estimates

The preparation of our condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, together with amounts disclosed in the related notes to the financial statements. Actual results and outcomes may differ from our estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these condensed consolidated financial statements include, but are not limited to, those related to revenue, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets, income taxes, the fair value of stock-based compensation and derivative financial instrument liabilities. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate.

Inventory

Inventory consists of raw materials, work-in-process and finished goods, all of which are valued at standard cost, which approximates average cost.

The following amounts were included in inventory at the end of the period:

June 30, December 31,

2017 2016

Raw materials $ 37,411 $ 45,964

Finished goods 155,698 160,009

Total $ 193,109 $ 205,973

Derivative Financial Instruments

We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. The terms of convertible preferred stock and convertible notes that we issue are reviewed to determine whether or not they contain embedded derivative instruments that are required by ASC 815: “Derivatives and Hedging” to be accounted for separately from the host contract, and recorded at fair value. In addition, freestanding warrants are also reviewed to determine if they achieve equity classification. Certain stock warrants that we have issued did not meet the conditions for equity classification and are classified as derivative instrument liabilities measured at fair value. The fair values of these derivative liabilities are revalued at each reporting date, with the change in fair value recognized in earnings. See Note 5 for additional information.

Fair Value Measurements

The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:

2017 2016

Balance at January 1 $ 7,900,249 $ 8,235,163

Warrants reclassified to equity — (51,417 )

Gain recognized in earnings (101,596 ) (232,614 )

Balance at June 30 $ 7,798,653 $ 7,951,132

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1

FINANCING AGREEMENTS
6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

FINANCING AGREEMENTS
NOTE 3 — FINANCING AGREEMENTS

Dow Facility

In December 2016, we entered into the Dow Facility which provides us with up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available if we have raised $10 million of equity capital after October 31, 2016.

The Dow Facility is senior to most of our other debt, and is secured by all of our assets (Dow is subordinate only to the capital leases with AAOF, see note 9). The loan does not mature until December 1, 2021 (subject to certain mandatory prepayments based on our equity financing activities). Interest is payable beginning January 1, 2017 although we may elect to capitalize interest through January 1, 2019. Dow received warrant coverage of one share of common stock for each $40 in loans received by us, equating to 20% warrant coverage, with an exercise price of $8.00 per share for the warrants issued at closing with the initial $2 million draw. After the initial closing, future warrants are subject to adjustment if we sell shares of common stock at a lower price. As of June 30, 2017, we had issued 50,000 warrants to Dow, which are exercisable on or before the expiration date of December 1, 2023.

The warrants meet the criteria for classification within stockholders’ equity. During the six months ended June 30, 2017, amortization expense of $56,340 was recognized resulting in a carrying value of $1,918,461 for the Dow Facility as of June 30, 2017.

The Dow Facility entitles Dow to appoint an observer to our board of directors (the “Board”). Dow will maintain their observation right until the later of December 1, 2019; or when the amount of principal and interest outstanding under the Dow Facility is less than $5 million.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1

PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS
6 Months Ended

Jun. 30, 2017

Warrants and Rights Note Disclosure [Abstract]

PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS
NOTE 4 — PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS

Private Placement

In April 2015, we commenced a private placement offering of Series B Units consisting of shares of Series B Preferred Stock and warrants to purchase common stock at an offering price of $16.00 per Series B Unit. During the period April 2015 through December 2016, we sold 266,887 shares of Series B Convertible Preferred Stock and Warrants to purchase 222,262 shares of common stock, for aggregate gross proceeds of $4,270,192.

The private placement Series B Unit offering was terminated on February 25, 2016. As a result of our IPO and pursuant to certain exchange rights granted to participants in the Series B Unit offering, holders of Series B Preferred Stock received the right to exchange each share of Series B Preferred Stock they owned into two shares of common stock. As of December 31, 2016, all holders of Series B Preferred Stock had exercised their Series B exchange rights, and as a result we issued 539,974 shares of restricted common stock in exchange for the 269,987 shares of Series B Preferred Stock that had been previously outstanding. All of the previously issued Series B Preferred Stock was cancelled. However, as of June 30, 2017, all of the 224,897 warrants issued in connection with the Series B Units remain outstanding. Such warrants have an exercise price of $16.00 per share and expire between April 21 and June 30, 2022.

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS
6 Months Ended

Jun. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE LIABILITY WARRANTS
NOTE 5 – DERIVATIVE LIABILITY WARRANTS

The Series A Convertible Preferred Stock warrants issued in conjunction with convertible notes issued in 2013 (subsequently converted into Series A Preferred Stock), equipment financing leases procured in 2013 and 2014, and certain other pre-emptive rights and the common stock warrants issued in connection with the 2015 Series B Unit offering are derivative liabilities which require re-measurement at fair value each reporting period. Liability classification is required because the terms of the underlying Series A Convertible Preferred Stock have a conversion price reset in the event we offer shares below the then current price of our common stock, and the exchange rights issued in connection with the Series B Unit offering are not consistent with the definition for financial instruments indexed only to a company’s own stock.

The initial value of the stock warrants issued as consideration for the equipment financing leases in 2013 and 2014 was recorded as a reduction of the capital lease obligation and is being amortized as part of the effective interest cost on the capital lease obligation (see Note 8).

In 2014 when we entered into financing agreements with Samsung, AAOF and XGS II, we provided our shareholders with preemptive rights to purchase shares of Series A Convertible Preferred Stock for every two shares of Series A Convertible Preferred Stock or Common Stock owned by the shareholder. In addition, for every two shares of Series A Convertible Preferred Stock purchased by a shareholder, we issued such shareholder a warrant to purchase one additional share of Series A Convertible Preferred Stock with the same terms as the warrants issued to AAOF and XGS II.

Also, as part of our private placement in April 2015, shareholders and holders of our convertible notes were provided the right to purchase their pro rata share of any class of stock that the Company sells or issues. The sale of Series B Preferred Stock in the April 2015 offering triggered the preemptive rights resulting in the issuance of shares of Series B Preferred Stock and warrants. As of June 30, 2017, the total number of Stock Warrants issued due to the preemptive rights offerings was 58,689.

Warrant shares indexed to derivative liabilities as of June 30, 2017 were as follows:

Type of
shares
indexed Exercise
Price Indexed
Shares

Warrants issued with Secured Convertible Notes Series A PS $ 6.40 833,333

Warrants issued with equipment financing leases Series A PS $ 6.40 83,333

Warrants issued with Series A preemptive rights Series A PS $ 6.40 56,054

Warrants issued with Series B preemptive rights Common $ 16.00 2,635

Warrants issued with Series B Units Common $ 16.00 222,262

Total shares indexed to derivative liabilities 1,197,617

The following table summarizes the fair value of the derivative liabilities as of June 30, 2017 and December 31, 2016:

June 30, 2017 December 31,2016

Warrants issued with Secured Convertible Notes $ 6,464,160 $ 6,554,160

Warrants issued with equipment financing leases 646,418 655,418

Warrants issued with preemptive rights 437,775 443,790

Warrants issued with 2015 Series B Unit private placement 250,300 246,881

Total derivative liabilities $ 7,798,653 $ 7,900,249

We estimated the fair value of their warrant derivative liabilities as of June 30, 2017 and December 31, 2016, using a lattice model and the following assumptions:

June 30, 2017 December 31, 2016

Fair value of underlying stock $8.00 - $12.64 $7.63 - $12.64

Equivalent risk free interest rate 1.43% - 1.56% 1.27%- 1.46%

Expected term (in years) 4.84 – 6.55 5.33- 7.04

Equivalent stock price volatility 37.49% - 37.69% 37.44%- 37.92%

Expected dividend yield — —

The value of the warrants is estimated using a binomial lattice model. Equivalent amounts reflect the net results of multiple modeling simulations that the lattice model applies to underlying assumptions. Because we are not publicly traded on a national exchange or to our knowledge, an over-the-counter market, the expected volatility of our common stock was developed using historical volatility for a peer group for a period equal to the expected term of the warrants. The fair value of the warrants will be significantly influenced by the fair value of our common stock, stock price volatility, and the risk-free interest components of the lattice technique.

Changes in the fair value of Derivative Liabilities, carried at fair value, are reported as “Change in fair value of derivative liability — warrants” in the Statement of Operations, and were as follows:

For the Three Months Ended
June 30, For the Six Months Ended
June 30,

2017 2016 2017 2016

Warrants issued with Secured Convertible Notes $ (17,500 ) $ 103,084 $ 90,000 $ 178,671

Warrants issued with equipment financing leases (1,750 ) 10,308 9,000 17,862

Warrants issued with preemptive rights (1,559 ) 7,197 6,015 12,281

Warrants issued with 2015 private placement (32,247 ) 22,259 (3,419 ) 22,541

Warrants issued with Bridge Financings — — — 1,259

Total Derivative Gain (Loss) $ (53,056 ) $ 142,848 $ 101,596 $ 232,614

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivatives and fair value of assets and liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_DerivativesAndFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1

STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS
6 Months Ended

Jun. 30, 2017

Equity [Abstract]

STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS
NOTE 6 – STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS

The following table summarizes the warrants outstanding at June 30, 2017, which are accounted for as equity instruments, all of which are exercisable:

Date Issued Expiration Date Exercise Price Number of
Warrants

7/1/2009 7/1/2019 $ 8.00 6,000

10/8/2012 10/8/2027 $ 12.00 5,000

12/14/2016 12/1/2023 $ 8.00 50,000

61,000

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_PreferredStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1

EQUITY INCENTIVE PLAN
6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

EQUITY INCENTIVE PLAN
NOTE 7 – EQUITY INCENTIVE PLAN

We previously established the 2007 Stock Option Plan (the “2007 Plan”), which was scheduled to expire on October 30, 2017 and under which we granted key employees and directors options to purchase shares of our common stock at not less than fair market value as of the grant date. On May 4, 2017, the Board approved the 2017 Equity Incentive Plan (the “2017 Plan”) to replace the 2007 Stock Option Plan, which became effective upon the approval of the stockholders holding a majority of the voting power in the Company on July 18, 2017. The 2017 Plan replaces the 2007 Plan and authorizes us to issue awards (stock options and restricted stock) with respect of a maximum of 1,200,000 shares of our common stock, which equals the number of shares authorized under the 2007 Plan, as amended.

On July 24, 2017, certain stock options from the prior incentive stock option plan were cancelled and replacement stock options were awarded. The new stock option awards have an exercise price of $8 per share, a seven-year term, are vested to the same extent as the cancelled stock options, and are subject to certain other terms. The cancellation and reissuance of the stock options were treated as a modification under ASC 718, Compensation-Stock Compensation. The incremental value resulting from the modification, is estimated to be approximately $330,000, which will be recorded as compensation cost on the date of cancellation (for vested awards) or over the remaining requisite service period (for unvested awards).

The fair values of options granted are estimated on the dates of grant using the Black Scholes option-pricing model. As of June 30, 2017, 369,750 options to acquire shares have been granted cumulatively. Vesting of the options granted range from immediately to 20% per year, with most new options vesting on a straight-line basis over a four year period from the date issued. Rights to exercise the options that would have vested in any current service year vest immediately upon a change in control of the Company. The options expire at various dates through October 2023.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1

CAPITAL LEASES
6 Months Ended

Jun. 30, 2017

Capital Leases of Lessee [Abstract]

CAPITAL LEASES
NOTE 8 – CAPITAL LEASES

As of June 30, 2017 and December 31, 2016, we have capital lease obligations as follows:

June 30, 2017 December 31, 2016

Capital lease obligations $ 295,340 $ 449,368

Unamortized warrant discount (34,705 ) (65,595 )

Net obligations 260,635 383,773

Short-term portion of obligations (200,768 ) (268,667 )

Long-term portion of obligations $ 59,867 $ 115,106

Our AAOF capital lease obligations are four year leases starting on January 1, 2014 and January 1, 2015. Our other capital leases expire at various dates in 2018, have average effective interest rates of 0% and contain bargain purchase options that allow us to purchase the leased property for a minimal amount upon the expiration of the lease term.

X

- References
No definition available.
+ Details

Name: us-gaap_CapitalLeasesOfLesseeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1

CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS
6 Months Ended

Jun. 30, 2017

Risks and Uncertainties [Abstract]

CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS
NOTE 9 — Customer, Supplier, country, and Product Concentrations

Grants and Licensing Revenue Concentration

There was no grant revenue for the three months ended June 30, 2017. During the six months ended June 30, 2017, one grantor accounted for 94% of total grant revenue. During the three months ended June 30, 2016 and the six months ended June 30, 2016, one grantor accounted for 100% of the total grant revenue in each period. Our licensing revenue for the three months ended June 30, 2017 and 2016, and for the six months ended June 30, 2017 and 2016 came from one licensor.

Product Concentration

Concentrations of product sales greater than 10% of total product sales are shown in the table below. We attempt to minimize the risk associated with product concentrations by continuing to develop new products to add to our portfolio.

For the Three Months Ended June 30, For the Six Months Ended June 30,

2017 2016 2017 2016

Grade C-300 HP 39% * 24% *

Grade C-500 * * 15% *

Grade C-750 * 11% * 11%

Grade R-10 15% 14% 12% 12%

Grade M-15 * * * 16%

Grade M-25 * 10% * *

* Denotes less than 10% of product sales.

Customer Concentration

During the three months ended June 30, 2017 we had two customers whose purchases accounted for 34% and 24% of product sales. During the three months ended June 30, 2016 we had one customer who accounted for 30% of product sales.

For the six months ended June 30, 2017 we had two customers whose purchases accounted for 15%, and 11% of product sales. During the six months ended June 30, 2016 we had two customers whose purchases accounted for 17% and 15% of product sales.

At June 30, 2017, there were two customers who each had an accounts receivable balance greater than 10% of our total outstanding receivable balance. At June 30, 2016, there was only one customer who had an accounts receivable balance greater than 10% of our total outstanding receivable balance.

Country Concentration

We sell our products on a worldwide basis. All of these sales are denominated in U.S. dollars.

International sales for the three months ended June 30, 2017 were 50% of product sales as compared with 72% for the three months ended June 30, 2016. One country, China, accounted for 25% of product sales for the three months ended June 30, 2017 and one country, South Korea, accounted for 40% of product sales for the three months ended June 30, 2016.

International sales for the six months ended June 30, 2017 were 60% of product sales as compared with 74% for the six months ended June 30, 2016. Three countries, China, South Korea, and the United Kingdom accounted for approximately 15%, 16%, and 14%, respectively, of product sales for the six months ended June 30, 2017 and one country, South Korea, accounted for 37% of product sales for the six months ended June 30, 2016.

Suppliers

We buy raw materials used in manufacturing from several sources. These materials are available from a large number of sources. Thus, we believe a change in suppliers would have no material effect on our operations. We did not have any purchases from one supplier that were more than 10% of total purchases for the three months and six months ended June 30, 2017 and 2016.

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1

RELATED PARTY TRANSACTIONS
6 Months Ended

Jun. 30, 2017

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
NOTE 10 - RELATED PARTY TRANSACTIONS

We have a licensing agreement for exclusive use of patents and pending patents with Michigan State University (“MSU”), a shareholder of the Company via the MSU Foundation. During the three months ended June 30, 2017 and 2016 we recorded licensing expense of $12,500 per quarter. During the six months ended June 30, 2017 and 2016 we recorded licensing expense of $25,000 in each period.

We have also entered into product licensing agreements with, POSCO, a shareholder. See below for POSCO. Other than MSU and POSCO, there were no other royalty expenses or revenue recognized during the three or six months ended June 30, 2017 and 2016.

Beginning in 2014, POSCO, a licensee and shareholder of the Company, has had a contractual obligation to pay a minimum royalty of $100,000 per year to license certain technologies. This obligation is due annually on February 28 of the following year. We record this license revenue at a rate of $25,000 per quarter. POSCO is disputing its obligation to pay the minimum royalty and has not paid the royalty in any prior year. We filed a demand for arbitration in the International Court of Arbitration (ICA) on March 9, 2016 in an effort to resolve the dispute. The ICA has assigned an arbitrator, but no decision has been reached in the dispute. Allowances in the amounts of $175,000 and $150,000 were recorded at June 30, 2017 and December 31, 2016, respectively, to reflect an estimate of the portion of the 2017, 2016, 2015 and 2014 royalties that we believe may not be collectible. The accrued royalty and allowance are netted together and reflected in other current assets on the condensed consolidated balance sheet.



On March 18, 2013, we entered into a series of agreements with two private investment funds: Aspen Advanced Opportunity Fund, LP (“AAOF”) and XGS II, LLC (“XGS II”), and pursuant to a Shareholders’ Agreement dated March 18, 2013 (as amended on February 26, 2016), a principal of each private fund serves as a member of our Board of Directors. These financing agreements were amended and restated on July 12, 2013 to provide for expanded financing commitments from AAOF and XGS II. Pursuant to these agreements, AAOF and XGS II agreed to provide $10 million of financing to the Company in the form of Secured Convertible Notes and AAOF agreed to provide an additional $1.0 million of lease financing arrangements. All of the principal and accrued interest on the Secured Convertible Notes issued to AAOF and XGS II were converted into Series A Preferred Stock in December 2016.

During the three months ended June 30, 2017 and 2016 we issued 7,140 shares per period of Series A Preferred stock to AAOF as payment for lease financing obligations under the terms of the Master Lease Agreement, dated March 18, 2013. For the six months ended June 30, 2017 and 2016 we issued a total of 14,280 shares per period as payment for lease obligations.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Liquidity
Liquidity

We have historically incurred losses from operations and we may continue to generate negative cash flows as we implement our business plan. Our condensed consolidated financial statements are prepared using US GAAP as applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

In December 2016, we entered into a draw loan note and agreement (the “Dow Facility”) with The Dow Chemical Company (“Dow”) to provide up to $10 million of secured debt financing at an interest rate of 5% per year, drawable at our request under certain conditions. We received $2 million at closing and an additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.

As of July 31, 2017, we had cash on hand of $1,000,702, and currently available funds of $2 million under the Dow Facility, which we believe will fund our operations for at least the next 12 months. We also have a commitment from a shareholder group, dated March 27, 2017, to provide up to $1 million of additional equity capital in the event we are unable to raise such funds from third party investors through the sale of our common stock in our initial public offering conducted pursuant to a Registration Statement on S-1 (Registration No. 333-209131) (the “IPO”). Our financial projections show that we may need to raise an additional $15 million or more before we are capable of achieving sustainable free cash flow after capital expenditures. We intend that the primary means for raising such funds will be through our IPO, the additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016. Thus far, we have raised $2.6 million through the sale of 323,578 shares of common stock between November 1, 2016 and June 30, 2017 towards the requirement to raise $10 million of additional equity capital in order to open up the remaining $5 million of availability on the Dow Facility. There can be no assurance that we will be able to raise additional equity capital in the IPO or in subsequent equity offerings or that the terms and conditions of any future financings will be workable or acceptable to us and our stockholders.

In the event we are unable to fund our operations from existing cash on hand, operating cash flows, additional borrowings or raising equity capital, we may be forced to reduce our expenses, slow down our growth rate, or discontinue operations. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Use of Estimates
Use of Estimates

The preparation of our condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, together with amounts disclosed in the related notes to the financial statements. Actual results and outcomes may differ from our estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these condensed consolidated financial statements include, but are not limited to, those related to revenue, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets, income taxes, the fair value of stock-based compensation and derivative financial instrument liabilities. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate.

Inventory
Inventory

Inventory consists of raw materials, work-in-process and finished goods, all of which are valued at standard cost, which approximates average cost.

The following amounts were included in inventory at the end of the period:

June 30, December 31,

2017 2016

Raw materials $ 37,411 $ 45,964

Finished goods 155,698 160,009

Total $ 193,109 $ 205,973

Derivative Financial Instruments
Derivative Financial Instruments

We do not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. The terms of convertible preferred stock and convertible notes that we issue are reviewed to determine whether or not they contain embedded derivative instruments that are required by ASC 815: “Derivatives and Hedging” to be accounted for separately from the host contract, and recorded at fair value. In addition, freestanding warrants are also reviewed to determine if they achieve equity classification. Certain stock warrants that we have issued did not meet the conditions for equity classification and are classified as derivative instrument liabilities measured at fair value. The fair values of these derivative liabilities are revalued at each reporting date, with the change in fair value recognized in earnings. See Note 5 for additional information.

Fair Value Measurements
Fair Value Measurements

The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:

2017 2016

Balance at January 1 $ 7,900,249 $ 8,235,163

Warrants reclassified to equity — (51,417 )

Gain recognized in earnings (101,596 ) (232,614 )

Balance at June 30 $ 7,798,653 $ 7,951,132

X

- Definition
The entire disclosure of liquidity.
+ References
No definition available.
+ Details

Name: cik0001435375_LiquidityPolicyTextBlock

Namespace Prefix: cik0001435375_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84234895&loc=d3e41620-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84234895&loc=SL5579240-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=84234895&loc=SL5579245-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84234895&loc=d3e41675-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84234895&loc=d3e41638-113959
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Schedule of inventory

The following amounts were included in inventory at the end of the period:

June 30, December 31,

2017 2016

Raw materials $ 37,411 $ 45,964

Finished goods 155,698 160,009

Total $ 193,109 $ 205,973

Schedule of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3)
The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2017 and 2016:

2017 2016

Balance at January 1 $ 7,900,249 $ 8,235,163

Warrants reclassified to equity — (51,417 )

Gain recognized in earnings (101,596 ) (232,614 )

Balance at June 30 $ 7,798,653 $ 7,951,132

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS (Tables)
6 Months Ended

Jun. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of shares indexed to derivative liabilities
Warrant shares indexed to derivative liabilities as of June 30, 2017 were as follows:

Type of
shares
indexed Exercise
Price Indexed
Shares

Warrants issued with Secured Convertible Notes Series A PS $ 6.40 833,333

Warrants issued with equipment financing leases Series A PS $ 6.40 83,333

Warrants issued with Series A preemptive rights Series A PS $ 6.40 56,054

Warrants issued with Series B preemptive rights Common $ 16.00 2,635

Warrants issued with Series B Units Common $ 16.00 222,262

Total shares indexed to derivative liabilities 1,197,617

Schedule of fair value of derivative liabilities
The following table summarizes the fair value of the derivative liabilities as of June 30, 2017 and December 31, 2016:

June 30, 2017 December 31,2016

Warrants issued with Secured Convertible Notes $ 6,464,160 $ 6,554,160

Warrants issued with equipment financing leases 646,418 655,418

Warrants issued with preemptive rights 437,775 443,790

Warrants issued with 2015 Series B Unit private placement 250,300 246,881

Total derivative liabilities $ 7,798,653 $ 7,900,249

Schedule of warrant derivative liabilities
We estimated the fair value of their warrant derivative liabilities as of June 30, 2017 and December 31, 2016, using a lattice model and the following assumptions:

June 30, 2017 December 31, 2016

Fair value of underlying stock $8.00 - $12.64 $7.63 - $12.64

Equivalent risk free interest rate 1.43% - 1.56% 1.27%- 1.46%

Expected term (in years) 4.84 – 6.55 5.33- 7.04

Equivalent stock price volatility 37.49% - 37.69% 37.44%- 37.92%

Expected dividend yield — —

Schedule of changes in fair value of derivative liability - warrants
Changes in the fair value of Derivative Liabilities, carried at fair value, are reported as “Change in fair value of derivative liability — warrants” in the Statement of Operations, and were as follows:

For the Three Months Ended
June 30, For the Six Months Ended
June 30,

2017 2016 2017 2016

Warrants issued with Secured Convertible Notes $ (17,500 ) $ 103,084 $ 90,000 $ 178,671

Warrants issued with equipment financing leases (1,750 ) 10,308 9,000 17,862

Warrants issued with preemptive rights (1,559 ) 7,197 6,015 12,281

Warrants issued with 2015 private placement (32,247 ) 22,259 (3,419 ) 22,541

Warrants issued with Bridge Financings — — — 1,259

Total Derivative Gain (Loss) $ (53,056 ) $ 142,848 $ 101,596 $ 232,614

X

- Definition
Tabular disclosure of change in fair value of derivative liability warrants.
+ References
No definition available.
+ Details

Name: cik0001435375_ScheduleOfChangeInFairValueOfDerivativeLiabilityWarrantsTableTextBlock

Namespace Prefix: cik0001435375_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of shares indexed to derivative liabilities.
+ References
No definition available.
+ Details

Name: cik0001435375_ScheduleOfSharesIndexedToDerivativeLiabilitiesTableTextBlock

Namespace Prefix: cik0001435375_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, used to measure similar assets in prior periods (non-recurring basis) by class of asset or liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of derivative liabilities at fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1

STOCK WARRANTS (Tables)
6 Months Ended

Jun. 30, 2017

Stock Warrants Tables

Schedule of warrants outstanding
The following table summarizes the warrants outstanding at June 30, 2017, which are accounted for as equity instruments, all of which are exercisable:

Date Issued Expiration Date Exercise Price Number of
Warrants

7/1/2009 7/1/2019 $ 8.00 6,000

10/8/2012 10/8/2027 $ 12.00 5,000

12/14/2016 12/1/2023 $ 8.00 50,000

61,000

X

- References
No definition available.
+ Details

Name: cik0001435375_StockWarrantsTablesAbstract

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1

CAPITAL LEASES (Tables)
6 Months Ended

Jun. 30, 2017

Capital Leases of Lessee [Abstract]

Schedule of capital lease obligations
As of June 30, 2017 and December 31, 2016, we have capital lease obligations as follows:

June 30, 2017 December 31, 2016

Capital lease obligations $ 295,340 $ 449,368

Unamortized warrant discount (34,705 ) (65,595 )

Net obligations 260,635 383,773

Short-term portion of obligations (200,768 ) (268,667 )

Long-term portion of obligations $ 59,867 $ 115,106

X

- References
No definition available.
+ Details

Name: us-gaap_CapitalLeasesOfLesseeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1

CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Tables)
6 Months Ended

Jun. 30, 2017

Customer Supplier Country And Product Concentrations Tables

Concentrations of product sales
Concentrations of product sales greater than 10% of total product sales are shown in the table below. We attempt to minimize the risk associated with product concentrations by continuing to develop new products to add to our portfolio.

For the Three Months Ended June 30, For the Six Months Ended June 30,

2017 2016 2017 2016

Grade C-300 HP 39% * 24% *

Grade C-500 * * 15% *

Grade C-750 * 11% * 11%

Grade R-10 15% 14% 12% 12%

Grade M-15 * * * 16%

Grade M-25 * 10% * *

* Denotes less than 10% of product sales.

X

- References
No definition available.
+ Details

Name: cik0001435375_CustomerSupplierCountryAndProductConcentrationsTablesAbstract

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6442-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6327-108592

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592
+ Details

Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)

Jun. 30, 2017

Dec. 31, 2016

Accounting Policies [Abstract]

Raw materials $ 37,411 $ 45,964

Finished goods 155,698 160,009

Total $ 193,109 $ 205,973

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - Significant Unobservable Inputs (Level 3) [Member] - Recurring [Member] - USD ($)
6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]

Balance at beginning $ 7,900,249 $ 8,235,163

Warrants reclassified to equity (51,417)

Gain recognized in earnings (101,596) (232,614)

Balance at ending $ 7,798,653 $ 7,951,132

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in the income statement of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 8 Months Ended

Jul. 31, 2017

Jul. 18, 2017

Dec. 31, 2016

Jun. 30, 2017

Jun. 30, 2017

Jun. 30, 2016

Dec. 31, 2015

Cash in hand $ 1,785,343 $ 431,107 $ 431,107 $ 959,787 $ 1,060,224

Funds available from operations 5,000,000

Additional fund required for next 12 months $ 10,000,000

Additional fund required for sustainable cash flow $ 15,000,000

Description of raising fund
Additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016.

Number of common shares sold 14,280 323,578

Value of common shares sold $ 1,720,400 $ 2,600,000

Subsequent Event [Member]

Cash in hand $ 1,000,702

Funds available from operations $ 2,000,000

The Dow Chemical Company [Member]

Description of raising fund
Additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.

The Dow Chemical Company [Member] | Draw Loan Note And Agreement [Member] | Senior Secured Debt Financing [Member]

Face amount 10,000,000

Proceeds from secured debt $ 2,000,000

Interest rate 5.00%

The Dow Chemical Company [Member] | Draw Loan Note And Agreement [Member] | Senior Secured Debt Financing [Member] | Subsequent Event [Member]

Proceeds from secured debt $ 1,000,000

X

- Definition
Additional fund required for next 12 months.
+ References
No definition available.
+ Details

Name: cik0001435375_AdditionalFundRequiredForNext12Months

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Additional fund required for sustainable cash flow.
+ References
No definition available.
+ Details

Name: cik0001435375_AdditionalFundRequiredForSustainableCashFlow

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of raising fund.
+ References
No definition available.
+ Details

Name: cik0001435375_DescriptionOfRaisingFund

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Funds available from operations.
+ References
No definition available.
+ Details

Name: cik0001435375_FundsAvailableFromOperations

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001435375_TheDowChemicalCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_DrawLoanNoteAndAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1

FINANCING AGREEMENTS (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended

Dec. 31, 2016

Jun. 30, 2017

Dec. 31, 2016

Number of common stock warrants issued 61,000

Warrant [Member]

Exercise price (in dollars per share) $ 12.00

Number of common stock warrants issued 5,000

Senior Secured Debt Financing [Member] | Draw Loan Note And Agreement [Member] | The Dow Chemical Company [Member]

Maturity date Dec. 01, 2021

Interest rate 5.00% 5.00%

Face amount $ 10,000,000 $ 10,000,000

Proceeds from secured debt $ 2,000,000

Description of funding
Additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available if we have raised $10 million of equity capital after October 31, 2016.

Description of collateral
Secured by all of our assets.

Description of interest payable terms
Payable beginning January 1, 2017 although we may elect to capitalize interest through January 1, 2019.

Amount of principal and interest outstanding $ 5,000,000

Senior Secured Debt Financing [Member] | Warrant [Member] | Draw Loan Note And Agreement [Member] | The Dow Chemical Company [Member]

Percentage of common stock warrant coverage 20.00%

Exercise price (in dollars per share) $ 8.00 $ 8.00

Number of common stock warrants issued 50,000

Description of warrant coverage
One share of common stock for each $40 in loans received by us, equating to 20% warrant coverage, with an exercise price of $8.00 per share for the warrants issued at closing with the initial $2 million draw.

Warrant expiration date Dec. 01, 2023

Amortization expense 56,340

Secured debt carrying amount $ 1,918,461

X

- Definition
Amount of principal and interest outstanding.
+ References
No definition available.
+ Details

Name: cik0001435375_AmountOfPrincipalAndInterestOutstanding

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Explanation of funding.
+ References
No definition available.
+ Details

Name: cik0001435375_DescriptionOfFunding

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Explanation of warrant.
+ References
No definition available.
+ Details

Name: cik0001435375_DescriptionOfWarrant

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Information related to number of warrants issued during period.
+ References
No definition available.
+ Details

Name: cik0001435375_NumberOfWarrantsIssuedDuringPeriod

Namespace Prefix: cik0001435375_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Information related to percentage of common stock warrant coverage.
+ References
No definition available.
+ Details

Name: cik0001435375_PercentageOfCommonStockWarrantCoverage

Namespace Prefix: cik0001435375_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Date which warrant is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: cik0001435375_WarrantExpirationDate

Namespace Prefix: cik0001435375_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentCollateral

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_SecuredLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cik0001435375_Warrant1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_DrawLoanNoteAndAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001435375_TheDowChemicalCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1

PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS (Details Narrative) - USD ($)
6 Months Ended 8 Months Ended 12 Months Ended 21 Months Ended

Feb. 25, 2016

Jun. 30, 2017

Jun. 30, 2017

Dec. 31, 2016

Dec. 31, 2016

Apr. 30, 2015

Number of shares issued 14,280 323,578

Warrant [Member]

Number of shares issued 1,197,617

Exercise price (in dollars per share) $ 8.00 $ 8.00

Private Placement [Member] | Warrant [Member]

Proceeds from private placement $ 4,270,192

Number of shares issued 222,262 222,262

Exercise price (in dollars per share) $ 16.00 $ 16.00

Number of warrants outstanding 224,897 224,897

Private Placement [Member] | Warrant [Member]

Share price (in dollars per unit) $ 16.00

Private Placement [Member] | Series B Preferred stock [Member]

Number of shares issued 266,887

Number of shares converted 269,987

Private Placement [Member] | Series B Preferred stock [Member] | Restricted Common Stock [Member]

Number of shares issued 539,974

X

- Definition
Per unit amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: cik0001435375_SaleOfStockPricePerShare1

Namespace Prefix: cik0001435375_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS (Details) - $ / shares
6 Months Ended 8 Months Ended

Feb. 25, 2016

Jun. 30, 2017

Jun. 30, 2017

Number of shares issued 14,280 323,578

Warrant [Member]

Number of shares issued 1,197,617

Exercise Price $ 8.00 $ 8.00

Warrant [Member] | Preemptive Rights Offering [Member]

Number of shares issued 58,689

Warrant [Member] | Private Placement [Member]

Number of shares issued 222,262 222,262

Exercise Price $ 16.00 16.00

Type of shares indexed Common

Warrant [Member] | Private Placement [Member] | Existing Stockholders [Member]

Number of shares issued 2,635

Exercise Price $ 16.00 16.00

Type of shares indexed Common

Warrant [Member] | Financing Agreements With Samsung, Ventures And Aspen Advanced Opportunity Fund LP, AAOF and XGS II [Member] | Preemptive Rights Offering [Member] | Series A Convertible Preferred Stock [Member]

Number of shares issued 56,054

Exercise Price $ 6.40 6.40

Type of shares indexed Series A PS

Secured Convertible Notes [Member] | Warrant [Member]

Number of shares issued 833,333

Exercise Price $ 6.40 6.40

Type of shares indexed Series A PS

Equipment Financing Leases [Member] | Warrant [Member]

Number of shares issued 83,333

Exercise Price $ 6.40 $ 6.40

Type of shares indexed Series A PS

X

- Definition
The entire disclosure for type of shares indexed.
+ References
No definition available.
+ Details

Name: cik0001435375_TypeOfSharesIndexed

Namespace Prefix: cik0001435375_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=cik0001435375_PreemptiveRightsOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001435375_ExistingStockholdersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_FinancingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS (Details 1) - USD ($)

Jun. 30, 2017

Dec. 31, 2016

Total derivative liabilities $ 7,798,653 $ 7,900,249

Financing Agreements With Samsung, Ventures And Aspen Advanced Opportunity Fund LP, AAOF and XGS II [Member] | Preemptive Rights Offering [Member] | Series A Convertible Preferred Stock [Member]

Total derivative liabilities 437,775 443,790

Warrant [Member] | Private Placement [Member]

Total derivative liabilities 250,300 246,881

Secured Convertible Notes [Member] | Warrant [Member]

Total derivative liabilities 6,464,160 6,554,160

Equipment Financing Leases [Member] | Warrant [Member]

Total derivative liabilities $ 646,418 $ 655,418

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13495-108611
+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_FinancingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=cik0001435375_PreemptiveRightsOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS (Details 2) - $ / shares
6 Months Ended 12 Months Ended

Jun. 30, 2017

Dec. 31, 2016

Expected dividend yield

Minimum [Member]

Fair value of underlying stock $ 8.00 $ 7.63

Equivalent risk free interest rate 1.43% 1.27%

Expected term (in years) 4 years 10 months 2 days 6 years 6 months 18 days

Equivalent stock price volatility 37.49% 37.44%

Maximum [Member]

Fair value of underlying stock $ 12.64 $ 12.64

Equivalent risk free interest rate 1.56% 1.46%

Expected term (in years) 5 years 6 months 18 days 7 years 4 months 24 days

Equivalent stock price volatility 37.69% 37.92%

X

- Definition
Agreed upon price for the exchange of the underlying asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk-free interest rate assumption used in valuing an instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS (Details 3) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Total Derivative Gain $ (53,056) $ 142,848 $ 101,596 $ 232,614

Warrant [Member] | Private Placement [Member]

Total Derivative Gain (32,247) 22,259 (3,419) 22,541

Warrant [Member] | Financing Agreements With Samsung, Ventures And Aspen Advanced Opportunity Fund LP, AAOF and XGS II [Member] | Preemptive Rights Offering [Member] | Series A Convertible Preferred Stock [Member]

Total Derivative Gain (1,559) 7,197 6,015 12,281

Secured Convertible Notes [Member] | Warrant [Member]

Total Derivative Gain (17,500) 103,084 90,000 178,671

Equipment Financing Leases [Member] | Warrant [Member]

Total Derivative Gain (1,750) 10,308 9,000 17,862

Bridge Financings [Member] | Warrant [Member] | 15 Investors [Member]

Total Derivative Gain $ 1,259

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84234895&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (a),(c),(d),(e)
-URI http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_FinancingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=cik0001435375_PreemptiveRightsOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_BridgeLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cik0001435375_Warrant1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1

DERIVATIVE LIABILITY WARRANTS (Details Narrative) - shares
6 Months Ended 8 Months Ended

Jun. 30, 2017

Jun. 30, 2017

Number of shares issued 14,280 323,578

Warrant [Member]

Number of shares issued 1,197,617

Warrant [Member] | Preemptive Rights Offering [Member]

Number of shares issued 58,689

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=cik0001435375_PreemptiveRightsOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1

STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS (Details)
6 Months Ended

Jun. 30, 2017

$ / shares

shares

Number of Warrants 61,000

Warrant [Member]

Date Issued Jul. 01, 2009

Expiration Date Jul. 01, 2019

Exercise Price | $ / shares $ 8.00

Number of Warrants 6,000

Warrant 1 [Member]

Date Issued Oct. 08, 2012

Expiration Date Oct. 08, 2027

Exercise Price | $ / shares $ 12.00

Number of Warrants 5,000

Warrant 2 [Member]

Date Issued Dec. 14, 2016

Expiration Date Dec. 01, 2023

Exercise Price | $ / shares $ 8.00

Number of Warrants 50,000

X

- Definition
Date the warrants or rights are exercisable, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: cik0001435375_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpiration

Namespace Prefix: cik0001435375_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the warrants or rights are exercisable, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: cik0001435375_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssued

Namespace Prefix: cik0001435375_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Information related to number of warrants issued during period.
+ References
No definition available.
+ Details

Name: cik0001435375_NumberOfWarrantsIssuedDuringPeriod

Namespace Prefix: cik0001435375_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cik0001435375_Warrant1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cik0001435375_Warrant2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1

EQUITY INCENTIVE PLAN (Details Narrative)
6 Months Ended

Jun. 30, 2017

USD ($)

$ / shares

shares

Incentive Stock Option Plan [Member]

Number of option granted 369,750

Vesting percent, per year 20.00%

Description of vesting terms
Vesting of the options granted range from immediately to 20% per year, with most new options vesting on a straight-line basis over a four year period from the date issued.

2007 Stock Option Plan [Member]

Exercise price (in dollars per share) | $ / shares $ 8

Vesting period 7 years

Compensation cost | $ $ 330,000

2007 Stock Option Plan [Member] | Maximum [Member]

Maximum number of options authorized 1,200,000

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=cik0001435375_IncentiveStockOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=cik0001435375_StockOptionPlan2007Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1

CAPITAL LEASES (Details) - USD ($)

Jun. 30, 2017

Dec. 31, 2016

Short-term portion of obligations $ (200,768) $ (268,667)

Long-term portion of obligations 59,867 115,106

Aspen Advance Opportunity Fund, LP [Member]

Capital lease obligations 295,340 449,368

Unamortized warrant discount (34,705) (65,595)

Net obligations 260,635 383,773

Short-term portion of obligations (200,768) (268,667)

Long-term portion of obligations $ 59,867 $ 115,106

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.
+ References
No definition available.
+ Details

Name: cik0001435375_CapitalLeaseObligationsGross

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Information related to unamortized warrant discount.
+ References
No definition available.
+ Details

Name: cik0001435375_UnamortizedWarrantDiscount

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_CapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735
+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=cik0001435375_AspenAdvanceOpportunityFundLPMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1

CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details) - Product Concentration Risk [Member] - Total Product Revenues [Member]
3 Months Ended 6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Grade C-300 HP [Member]

Concentration of risk 39.00% ^[1] 24.00% ^[1]

Grade C-500 [Member]

Concentration of risk ^[1] ^[1] 15.00% ^[1]

Grade C-750 [Member]

Concentration of risk ^[1] 11.00% ^[1] 11.00%

Grade R-10 [Member]

Concentration of risk 15.00% 14.00% 12.00% 12.00%

Grade M-15 [Member]

Concentration of risk ^[1] ^[1] ^[1] 16.00%

Grade M-25 [Member]

Concentration of risk ^[1] 10.00% ^[1] ^[1]

[1] Denotes less than 10% of product sales.

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=cik0001435375_ProductOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=cik0001435375_ProductTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=cik0001435375_ProductThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=cik0001435375_ProductFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=cik0001435375_ProductFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=cik0001435375_ProductSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1

CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details Narrative) - Customer
3 Months Ended 6 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Grants and Licensing Revenue Concentration [Member] | Total Grant Revenue [Member] | Grantor One [Member]

Concentration of risk 100.00% 94.00% 100.00%

Customer Concentration Risk [Member] | Total Product Revenues [Member] | Customer One [Member]

Concentration of risk 34.00% 15.00% 17.00%

Customer Concentration Risk [Member] | Total Product Revenues [Member] | Customer Two [Member]

Concentration of risk 24.00% 11.00% 15.00%

Customer Concentration Risk [Member] | Total Product Revenues [Member] | Customer [Member]

Concentration of risk 30.00%

Number of customers 2 2 2 2

Customer Concentration Risk [Member] | Accounts Receivable Greater Than 10% [Member] | Customer [Member]

Number of customers 2 1 2 1

Country Concentration Risk [Member] | Total Product Revenues [Member] | China

Concentration of risk 25.00% 15.00%

Country Concentration Risk [Member] | Total Product Revenues [Member] | Korea (South)

Concentration of risk 40.00% 16.00% 37.00%

Country Concentration Risk [Member] | Total Product Revenues [Member] | United Kingdom

Concentration of risk 14.00%

Country Concentration Risk [Member] | Total Product Revenues [Member] | Foreign [Member]

Concentration of risk 50.00% 72.00% 60.00% 74.00%

X

- Definition
Represents the number of customers.
+ References
No definition available.
+ Details

Name: cik0001435375_NumberOfCustomers

Namespace Prefix: cik0001435375_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=cik0001435375_GrantsAndLicensingRevenueConcentrationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=cik0001435375_GrantRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001435375_GrantorOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=cik0001435375_CustomerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=cik0001435375_CustomerTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=cik0001435375_CustomerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=currency_KRW

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_GB

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 8 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Dec. 31, 2016

Mar. 18, 2013

Number of shares issued 14,280 323,578

Licensing Agreement [Member] | Aspen Advance Opportunity Fund, LP (AAOF) [Member]

Lease financing $ 1,000,000

Licensing Agreement [Member] | Aspen Advanced Opportunity Fund, LP ("AAOF") and XGS II, LLC ("XGS II") [Member] | Secured Convertible Notes [Member]

Lease financing $ 10,000,000

Licensing Agreement [Member] | Michigan State University (Patents and Pending Patents) [Member]

Licensing expenses $ 12,500 $ 12,500 $ 25,000 $ 25,000

Licensing Agreement [Member] | POSCO [Member]

Minimum yearly contractual obligation 100,000 100,000 $ 100,000

Quarterly license revenue 25,000 25,000 25,000

Allowance contractual obligation $ 175,000 $ 175,000 $ 175,000 $ 150,000

Master Leasing Agreement [Member] | Aspen Advance Opportunity Fund, LP (AAOF) [Member] | Series A Preferred stock [Member]

Number of shares issued 7,140 7,140 14,280 14,280

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
No definition available.
+ Details

Name: cik0001435375_ContractualObligation1

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
No definition available.
+ Details

Name: cik0001435375_ContractualObligationAllowance

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lease financing.
+ References
No definition available.
+ Details

Name: cik0001435375_LeaseFinancing

Namespace Prefix: cik0001435375_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_LicensingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001435375_AspenAdvanceOpportunityFundLPMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cik0001435375_AAOFAndXGSIIMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001435375_MichiganStateUniversityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cik0001435375_POSCOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=cik0001435375_MasterLeasingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 164 173 1 true 58 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://xgsciences.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://xgsciences.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://xgsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://xgsciences.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIT) (unaudited) Sheet http://xgsciences.com/role/CondensedConsolidatedStatementOfChangesInStockholdersDeficit CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIT) (unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://xgsciences.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://xgsciences.com/role/NatureOfBusinessAndBasisOfPresentation NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://xgsciences.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - FINANCING AGREEMENTS Sheet http://xgsciences.com/role/FinancingAgreements FINANCING AGREEMENTS Notes 9 false false R10.htm 00000010 - Disclosure - PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS Sheet http://xgsciences.com/role/PrivatePlacementAndPreemptiveRights PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS Notes 10 false false R11.htm 00000011 - Disclosure - DERIVATIVE LIABILITY WARRANTS Sheet http://xgsciences.com/role/DerivativeLiabilityWarrants DERIVATIVE LIABILITY WARRANTS Notes 11 false false R12.htm 00000012 - Disclosure - STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS Sheet http://xgsciences.com/role/StockWarrantsAccountedForAsEquityInstruments STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS Notes 12 false false R13.htm 00000013 - Disclosure - EQUITY INCENTIVE PLAN Sheet http://xgsciences.com/role/EquityIncentivePlan EQUITY INCENTIVE PLAN Notes 13 false false R14.htm 00000014 - Disclosure - CAPITAL LEASES Sheet http://xgsciences.com/role/CapitalLeases CAPITAL LEASES Notes 14 false false R15.htm 00000015 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS Sheet http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrations CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://xgsciences.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://xgsciences.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Tables) Sheet http://xgsciences.com/role/DerivativeLiabilityWarrantsTables DERIVATIVE LIABILITY WARRANTS (Tables) Tables http://xgsciences.com/role/DerivativeLiabilityWarrants 19 false false R20.htm 00000020 - Disclosure - STOCK WARRANTS (Tables) Sheet http://xgsciences.com/role/StockWarrantsTables STOCK WARRANTS (Tables) Tables http://xgsciences.com/role/StockWarrantsAccountedForAsEquityInstruments 20 false false R21.htm 00000021 - Disclosure - CAPITAL LEASES (Tables) Sheet http://xgsciences.com/role/CapitalLeasesTables CAPITAL LEASES (Tables) Tables http://xgsciences.com/role/CapitalLeases 21 false false R22.htm 00000022 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Tables) Sheet http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrationsTables CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Tables) Tables http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrations 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesDetails1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://xgsciences.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - FINANCING AGREEMENTS (Details Narrative) Sheet http://xgsciences.com/role/FinancingAgreementsDetailsNarrative FINANCING AGREEMENTS (Details Narrative) Details http://xgsciences.com/role/FinancingAgreements 26 false false R27.htm 00000027 - Disclosure - PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS (Details Narrative) Sheet http://xgsciences.com/role/PrivatePlacementAndPreemptiveRightsDetailsNarrative PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS (Details Narrative) Details http://xgsciences.com/role/PrivatePlacementAndPreemptiveRights 27 false false R28.htm 00000028 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details) Sheet http://xgsciences.com/role/DerivativeLiabilityWarrantsDetails DERIVATIVE LIABILITY WARRANTS (Details) Details http://xgsciences.com/role/DerivativeLiabilityWarrantsTables 28 false false R29.htm 00000029 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details 1) Sheet http://xgsciences.com/role/DerivativeLiabilityWarrantsDetails1 DERIVATIVE LIABILITY WARRANTS (Details 1) Details http://xgsciences.com/role/DerivativeLiabilityWarrantsTables 29 false false R30.htm 00000030 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details 2) Sheet http://xgsciences.com/role/DerivativeLiabilityWarrantsDetails2 DERIVATIVE LIABILITY WARRANTS (Details 2) Details http://xgsciences.com/role/DerivativeLiabilityWarrantsTables 30 false false R31.htm 00000031 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details 3) Sheet http://xgsciences.com/role/DerivativeLiabilityWarrantsDetails3 DERIVATIVE LIABILITY WARRANTS (Details 3) Details http://xgsciences.com/role/DerivativeLiabilityWarrantsTables 31 false false R32.htm 00000032 - Disclosure - DERIVATIVE LIABILITY WARRANTS (Details Narrative) Sheet http://xgsciences.com/role/DerivativeLiabilityWarrantsDetailsNarrative DERIVATIVE LIABILITY WARRANTS (Details Narrative) Details http://xgsciences.com/role/DerivativeLiabilityWarrantsTables 32 false false R33.htm 00000033 - Disclosure - STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS (Details) Sheet http://xgsciences.com/role/StockWarrantsAccountedForAsEquityInstrumentsDetails STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS (Details) Details http://xgsciences.com/role/StockWarrantsAccountedForAsEquityInstruments 33 false false R34.htm 00000034 - Disclosure - EQUITY INCENTIVE PLAN (Details Narrative) Sheet http://xgsciences.com/role/EquityIncentivePlanDetailsNarrative EQUITY INCENTIVE PLAN (Details Narrative) Details http://xgsciences.com/role/EquityIncentivePlan 34 false false R35.htm 00000035 - Disclosure - CAPITAL LEASES (Details) Sheet http://xgsciences.com/role/CapitalLeasesDetails CAPITAL LEASES (Details) Details http://xgsciences.com/role/CapitalLeasesTables 35 false false R36.htm 00000036 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details) Sheet http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrationsDetails CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details) Details http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrationsTables 36 false false R37.htm 00000037 - Disclosure - CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details Narrative) Sheet http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrationsDetailsNarrative CUSTOMER, SUPPLIER, COUNTRY AND PRODUCT CONCENTRATIONS (Details Narrative) Details http://xgsciences.com/role/CustomerSupplierCountryAndProductConcentrationsTables 37 false false R38.htm 00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://xgsciences.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://xgsciences.com/role/RelatedPartyTransactions 38 false false All Reports Book All Reports cik0001435375-20170630.xml cik0001435375-20170630.xsd cik0001435375-20170630_cal.xml cik0001435375-20170630_def.xml cik0001435375-20170630_lab.xml cik0001435375-20170630_pre.xml true true ZIP 60 0001615774-17-004270-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-17-004270-xbrl.zip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�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

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 11, 2017
Document And Entity Information
Entity Registrant Name	XG SCIENCES INC
Entity Central Index Key	0001435375
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,100,225
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 431,107	$ 1,785,343
Accounts receivable, less allowance for doubtful accounts of $10,000 at June 30, 2017 and December 31, 2016	131,607	99,078
Inventory	193,109	205,973
Incentive refunds receivable		165,635
Other current assets	213,789	174,495
Total current assets	969,612	2,430,524
PROPERTY, PLANT AND EQUIPMENT, NET	2,799,346	2,886,421
RESTRICTED CASH FOR LETTER OF CREDIT	195,644	195,499
INTANGIBLE ASSETS, NET	551,462	478,019
TOTAL ASSETS	4,516,064	5,990,463
CURRENT LIABILITIES
Accounts payable and other liabilities	750,359	964,757
Deferred revenue	7,120	6,428
Current portion of capital lease obligations	200,768	268,667
Total current liabilities	958,247	1,239,852
LONG TERM LIABILITIES
Long term portion of capital lease obligations	59,867	115,106
Long term debt	1,918,461	1,862,120
Derivative liability - warrants	7,798,653	7,900,249
Total long term liabilities	9,776,981	9,877,475
TOTAL LIABILITIES	10,735,228	11,117,327
STOCKHOLDERS' DEFICIT
Common stock, no par value, 25,000,000 shares authorized, 2,100,225 and 1,885,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	17,134,739	15,647,839
Additional paid in capital	6,666,972	6,490,230
Accumulated deficit	(51,826,815)	(48,899,530)
Total stockholders' deficit	(6,219,164)	(5,126,864)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	4,516,064	5,990,463
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, value	21,805,940	21,634,597
Series B Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, value

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Allowance for doubtful accounts	$ 10,000	$ 10,000
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, authorized	25,000,000	25,000,000
Common stock, issued	2,100,225	1,885,175
Common stock, outstanding	2,100,225	1,885,175
Series A Convertible Preferred Stock [Member]
Preferred stock, authorized	3,000,000	3,000,000
Preferred stock, issued	1,843,536	1,829,256
Preferred stock, outstanding	1,843,536	1,829,256
Preferred stock, liquidation value	$ 22,122,432	$ 21,951,072
Series B Preferred stock [Member]
Preferred stock, authorized	1,500,000	1,500,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Preferred stock, liquidation value	$ 0	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
REVENUE
Product sales	$ 259,079	$ 82,035	$ 416,779	$ 141,777
Grants		137,055	99,489	158,365
Licensing revenue	25,000	25,000	50,000	50,000
Total revenue	284,079	244,090	566,268	350,142
COST OF GOODS SOLD
Direct costs	93,542	25,020	210,312	57,052
Unallocated manufacturing expenses	415,152	404,232	786,302	747,947
Total cost of goods sold	508,694	429,252	996,614	804,999
GROSS LOSS	(224,615)	(185,162)	(430,346)	(454,857)
OPERATING EXPENSES
Research and development	227,062	419,007	490,626	635,357
Sales, general and administrative	923,765	625,381	1,920,352	1,721,603
Total operating expenses	1,150,827	1,044,388	2,410,978	2,356,960
OPERATING LOSS	(1,375,442)	(1,229,550)	(2,841,324)	(2,811,817)
OTHER INCOME (EXPENSE)
Interest expense, net	(54,445)	(101,123)	(113,533)	(184,774)
Gain (Loss) from change in fair value of derivative liability - warrants	(53,056)	142,848	101,596	232,614
Government incentives, net	(74,000)	24,000	(74,024)	48,000
Total other income (expense)	(181,501)	65,725	(85,961)	95,840
NET LOSS	$ (1,556,943)	$ (1,163,825)	$ (2,927,285)	$ (2,715,977)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic and diluted (in shares)	2,054,999	887,595	1,951,406	862,069
NET LOSS PER SHARE - Basic and diluted (in dollars per share)	$ (0.76)	$ (1.31)	$ (1.47)	$ (3.15)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIT) (unaudited) - 6 months ended Jun. 30, 2017 - USD ($)	Series A Preferred stock [Member]	Common stock [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]	Total
Balances at beginning at Dec. 31, 2016	$ 21,634,597	$ 15,647,839	$ 6,490,230	$ (48,899,530)	$ (5,126,864)
Balances at beginning (in shares) at Dec. 31, 2016	1,829,256	1,885,175
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued for cash		$ 1,720,400			$ 1,720,400
Stock issued for cash (in shares)		215,050			14,280
Stock issuance fees and expenses		$ (233,500)			$ (233,500)
Preferred stock issued to pay capital lease obligations	$ 171,343				171,343
Preferred stock issued to pay capital lease obligations (in shares)	14,280
Employee stock option expense			176,742		176,742
Net loss				(2,927,285)	(2,927,285)
Balances at ending at Jun. 30, 2017	$ 21,805,940	$ 17,134,739	$ 6,666,972	$ (51,826,815)	$ (6,219,164)
Balances at ending (in shares) at Jun. 30, 2017	1,843,536	2,100,225

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,927,285)	$ (2,715,977)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	439,078	456,133
Amortization of intangible assets	21,180	17,904
Stock-based compensation expense	176,742	228,126
Non-cash interest expense	114,295	157,903
Gain from change in fair value of derivative liability - warrants	(101,596)	(232,614)
(Increase) Decrease in:
Accounts receivable	(32,529)	5,930
Inventory	12,864	12,624
Other current and non-current assets	126,196	(79,461)
Increase (Decrease) in:
Accounts payable and other liabilities	(213,705)	371,606
NET CASH USED IN OPERATING ACTIVITIES	(2,384,760)	(1,777,826)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(352,003)	(39,314)
Purchases of intangible assets	(94,623)	(53,647)
NET CASH USED IN INVESTING ACTIVITIES	(446,626)	(92,961)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of capital lease obligations	(9,750)	(2,832)
Repayments of short-term notes		(750,000)
Advances on short-term notes		574,750
Proceeds from issuance of common stock	1,720,400	2,285,032
Common stock issuance fees and expenses	(233,500)	(336,600)
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,477,150	1,770,350
NET DECREASE IN CASH	(1,354,236)	(100,437)
CASH AT BEGINNING OF PERIOD	1,785,343	1,060,224
CASH AT END OF PERIOD	431,107	959,787
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest		77,646
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING:
Value of preferred stock issued for AAOF capital lease obligations	$ 171,343	$ 171,343

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Raw materials	$ 37,411	$ 45,964
Finished goods	155,698	160,009
Total	$ 193,109	$ 205,973

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - Significant Unobservable Inputs (Level 3) [Member] - Recurring [Member] - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at beginning	$ 7,900,249	$ 8,235,163
Warrants reclassified to equity		(51,417)
Gain recognized in earnings	(101,596)	(232,614)
Balance at ending	$ 7,798,653	$ 7,951,132

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended	8 Months Ended
	Jul. 31, 2017	Jul. 18, 2017	Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2015
Cash in hand			$ 1,785,343	$ 431,107	$ 431,107	$ 959,787	$ 1,060,224
Funds available from operations					5,000,000
Additional fund required for next 12 months					$ 10,000,000
Additional fund required for sustainable cash flow				$ 15,000,000
Description of raising fund				Additional $2 million of currently available funds under the Dow Facility, and up to an additional $5 million of proceeds from the Dow Facility in the event that we raise $10 million of additional equity capital after October 31, 2016.
Number of common shares sold				14,280	323,578
Value of common shares sold				$ 1,720,400	$ 2,600,000
Subsequent Event [Member]
Cash in hand	$ 1,000,702
Funds available from operations	$ 2,000,000
The Dow Chemical Company [Member]
Description of raising fund				Additional $5 million becomes available under the Dow Facility if we have raised $10 million of equity capital after October 31, 2016.
The Dow Chemical Company [Member] \| Draw Loan Note And Agreement [Member] \| Senior Secured Debt Financing [Member]
Face amount			10,000,000
Proceeds from secured debt			$ 2,000,000
Interest rate			5.00%
The Dow Chemical Company [Member] \| Draw Loan Note And Agreement [Member] \| Senior Secured Debt Financing [Member] \| Subsequent Event [Member]
Proceeds from secured debt		$ 1,000,000

FINANCING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
FINANCING AGREEMENTS (Details Narrative) - USD ($)	Dec. 31, 2016	Jun. 30, 2017	Dec. 31, 2016
Number of common stock warrants issued		61,000
Warrant [Member]
Exercise price (in dollars per share)		$ 12.00
Number of common stock warrants issued		5,000
Senior Secured Debt Financing [Member] \| Draw Loan Note And Agreement [Member] \| The Dow Chemical Company [Member]
Maturity date	Dec. 01, 2021
Interest rate	5.00%		5.00%
Face amount	$ 10,000,000		$ 10,000,000
Proceeds from secured debt	$ 2,000,000
Description of funding	Additional $1 million on July 18, 2017. We currently have $2 million of additional funding available on or before December 1, 2017 under the Dow Facility. After December 1, 2017, an additional $5 million becomes available if we have raised $10 million of equity capital after October 31, 2016.
Description of collateral	Secured by all of our assets.
Description of interest payable terms	Payable beginning January 1, 2017 although we may elect to capitalize interest through January 1, 2019.
Amount of principal and interest outstanding		$ 5,000,000
Senior Secured Debt Financing [Member] \| Warrant [Member] \| Draw Loan Note And Agreement [Member] \| The Dow Chemical Company [Member]
Percentage of common stock warrant coverage	20.00%
Exercise price (in dollars per share)	$ 8.00		$ 8.00
Number of common stock warrants issued			50,000
Description of warrant coverage	One share of common stock for each $40 in loans received by us, equating to 20% warrant coverage, with an exercise price of $8.00 per share for the warrants issued at closing with the initial $2 million draw.
Warrant expiration date			Dec. 01, 2023
Amortization expense		56,340
Secured debt carrying amount		$ 1,918,461

PRIVATE PLACEMENT AND PREEMPTIVE RIGHTS (Details Narrative) - USD ($)		6 Months Ended	8 Months Ended	12 Months Ended	21 Months Ended
	Feb. 25, 2016	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2016	Apr. 30, 2015
Number of shares issued		14,280	323,578
Warrant [Member]
Number of shares issued		1,197,617
Exercise price (in dollars per share)		$ 8.00	$ 8.00
Private Placement [Member] \| Warrant [Member]
Proceeds from private placement		$ 4,270,192
Number of shares issued	222,262	222,262
Exercise price (in dollars per share)		$ 16.00	$ 16.00
Number of warrants outstanding		224,897	224,897
Private Placement [Member] \| Warrant [Member]
Share price (in dollars per unit)						$ 16.00
Private Placement [Member] \| Series B Preferred stock [Member]
Number of shares issued					266,887
Number of shares converted				269,987
Private Placement [Member] \| Series B Preferred stock [Member] \| Restricted Common Stock [Member]
Number of shares issued				539,974

DERIVATIVE LIABILITY WARRANTS (Details) - $ / shares		6 Months Ended	8 Months Ended
DERIVATIVE LIABILITY WARRANTS (Details) - $ / shares	Feb. 25, 2016	Jun. 30, 2017	Jun. 30, 2017
Number of shares issued		14,280	323,578
Warrant [Member]
Number of shares issued		1,197,617
Exercise Price		$ 8.00	$ 8.00
Warrant [Member] \| Preemptive Rights Offering [Member]
Number of shares issued		58,689
Warrant [Member] \| Private Placement [Member]
Number of shares issued	222,262	222,262
Exercise Price		$ 16.00	16.00
Type of shares indexed		Common
Warrant [Member] \| Private Placement [Member] \| Existing Stockholders [Member]
Number of shares issued		2,635
Exercise Price		$ 16.00	16.00
Type of shares indexed		Common
Warrant [Member] \| Financing Agreements With Samsung, Ventures And Aspen Advanced Opportunity Fund LP, AAOF and XGS II [Member] \| Preemptive Rights Offering [Member] \| Series A Convertible Preferred Stock [Member]
Number of shares issued		56,054
Exercise Price		$ 6.40	6.40
Type of shares indexed		Series A PS
Secured Convertible Notes [Member] \| Warrant [Member]
Number of shares issued		833,333
Exercise Price		$ 6.40	6.40
Type of shares indexed		Series A PS
Equipment Financing Leases [Member] \| Warrant [Member]
Number of shares issued		83,333
Exercise Price		$ 6.40	$ 6.40
Type of shares indexed		Series A PS

STOCK WARRANTS ACCOUNTED FOR AS EQUITY INSTRUMENTS (Details)	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Number of Warrants	61,000
Warrant [Member]
Date Issued	Jul. 01, 2009
Expiration Date	Jul. 01, 2019
Exercise Price \| $ / shares	$ 8.00
Number of Warrants	6,000
Warrant 1 [Member]
Date Issued	Oct. 08, 2012
Expiration Date	Oct. 08, 2027
Exercise Price \| $ / shares	$ 12.00
Number of Warrants	5,000
Warrant 2 [Member]
Date Issued	Dec. 14, 2016
Expiration Date	Dec. 01, 2023
Exercise Price \| $ / shares	$ 8.00
Number of Warrants	50,000

EQUITY INCENTIVE PLAN (Details Narrative)	6 Months Ended
EQUITY INCENTIVE PLAN (Details Narrative)	Jun. 30, 2017 USD ($) $ / shares shares
Incentive Stock Option Plan [Member]
Number of option granted	369,750
Vesting percent, per year	20.00%
Description of vesting terms	Vesting of the options granted range from immediately to 20% per year, with most new options vesting on a straight-line basis over a four year period from the date issued.
2007 Stock Option Plan [Member]
Exercise price (in dollars per share) \| $ / shares	$ 8
Vesting period	7 years
Compensation cost \| $	$ 330,000
2007 Stock Option Plan [Member] \| Maximum [Member]
Maximum number of options authorized	1,200,000

CAPITAL LEASES (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Short-term portion of obligations	$ (200,768)	$ (268,667)
Long-term portion of obligations	59,867	115,106
Aspen Advance Opportunity Fund, LP [Member]
Capital lease obligations	295,340	449,368
Unamortized warrant discount	(34,705)	(65,595)
Net obligations	260,635	383,773
Short-term portion of obligations	(200,768)	(268,667)
Long-term portion of obligations	$ 59,867	$ 115,106